WO2022211051A1 - 抗egfr抗体の放射性複合体、及び、放射性医薬 - Google Patents
抗egfr抗体の放射性複合体、及び、放射性医薬 Download PDFInfo
- Publication number
- WO2022211051A1 WO2022211051A1 PCT/JP2022/016647 JP2022016647W WO2022211051A1 WO 2022211051 A1 WO2022211051 A1 WO 2022211051A1 JP 2022016647 W JP2022016647 W JP 2022016647W WO 2022211051 A1 WO2022211051 A1 WO 2022211051A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- complex
- group
- chelating agent
- peptide
- Prior art date
Links
- 239000012217 radiopharmaceutical Substances 0.000 title claims description 53
- 229940121896 radiopharmaceutical Drugs 0.000 title claims description 53
- 230000002799 radiopharmaceutical effect Effects 0.000 title claims description 53
- 230000002285 radioactive effect Effects 0.000 title description 29
- 239000002738 chelating agent Substances 0.000 claims abstract description 109
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 100
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 24
- UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 131
- 229960001972 panitumumab Drugs 0.000 claims description 49
- 150000001413 amino acids Chemical class 0.000 claims description 41
- 125000000539 amino acid group Chemical group 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 33
- 229960005395 cetuximab Drugs 0.000 claims description 29
- 235000001014 amino acid Nutrition 0.000 claims description 25
- 238000012650 click reaction Methods 0.000 claims description 22
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 17
- 239000003431 cross linking reagent Substances 0.000 claims description 15
- 238000001959 radiotherapy Methods 0.000 claims description 14
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 11
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 9
- 125000005179 haloacetyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 7
- YOFPFYYTUIARDI-ZCFIWIBFSA-N (2r)-2-aminooctanedioic acid Chemical compound OC(=O)[C@H](N)CCCCCC(O)=O YOFPFYYTUIARDI-ZCFIWIBFSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- DZTVAULYUGBHSF-UHFFFAOYSA-N 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 DZTVAULYUGBHSF-UHFFFAOYSA-N 0.000 claims description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 3
- 125000003827 glycol group Chemical group 0.000 claims description 2
- SKWCZPYWFRTSDD-UHFFFAOYSA-N 2,3-bis(azaniumyl)propanoate;chloride Chemical compound Cl.NCC(N)C(O)=O SKWCZPYWFRTSDD-UHFFFAOYSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 13
- 210000004027 cell Anatomy 0.000 description 84
- 125000005647 linker group Chemical group 0.000 description 70
- 239000000243 solution Substances 0.000 description 63
- 230000027455 binding Effects 0.000 description 38
- 102000001301 EGF receptor Human genes 0.000 description 37
- 108060006698 EGF receptor Proteins 0.000 description 36
- 238000004519 manufacturing process Methods 0.000 description 35
- 238000000034 method Methods 0.000 description 33
- 238000011156 evaluation Methods 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 27
- 241000282414 Homo sapiens Species 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 230000000259 anti-tumor effect Effects 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 230000009918 complex formation Effects 0.000 description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 238000002372 labelling Methods 0.000 description 17
- 239000000562 conjugate Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 230000037396 body weight Effects 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 239000007974 sodium acetate buffer Substances 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000013522 chelant Substances 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- OUCMTIKCFRCBHK-UHFFFAOYSA-N 3,3-dibenzylcyclooctyne Chemical compound C1CCCCC#CC1(CC=1C=CC=CC=1)CC1=CC=CC=C1 OUCMTIKCFRCBHK-UHFFFAOYSA-N 0.000 description 11
- -1 In-111 Chemical compound 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 206010009944 Colon cancer Diseases 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 239000004471 Glycine Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 230000005855 radiation Effects 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- URYYVOIYTNXXBN-OWOJBTEDSA-N trans-cyclooctene Chemical compound C1CCC\C=C\CC1 URYYVOIYTNXXBN-OWOJBTEDSA-N 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 150000001345 alkine derivatives Chemical class 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 150000001540 azides Chemical class 0.000 description 7
- LNQHREYHFRFJAU-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) pentanedioate Chemical group O=C1CCC(=O)N1OC(=O)CCCC(=O)ON1C(=O)CCC1=O LNQHREYHFRFJAU-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 230000022534 cell killing Effects 0.000 description 7
- 239000007979 citrate buffer Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 229940049595 antibody-drug conjugate Drugs 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 229910021645 metal ion Inorganic materials 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000002600 positron emission tomography Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 239000008351 acetate buffer Substances 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 230000005782 double-strand break Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000036326 tumor accumulation Effects 0.000 description 5
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 4
- FQIHLPGWBOBPSG-UHFFFAOYSA-N 2-[4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetamide Chemical compound NC(=O)CN1CCN(CC(N)=O)CCN(CC(N)=O)CCN(CC(N)=O)CC1 FQIHLPGWBOBPSG-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 206010029155 Nephropathy toxic Diseases 0.000 description 4
- 238000012879 PET imaging Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 101710120037 Toxin CcdB Proteins 0.000 description 4
- 238000010162 Tukey test Methods 0.000 description 4
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 210000003855 cell nucleus Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007694 nephrotoxicity Effects 0.000 description 4
- 231100000417 nephrotoxicity Toxicity 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 231100000161 signs of toxicity Toxicity 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000047934 Caspase-3/7 Human genes 0.000 description 3
- 108700037887 Caspase-3/7 Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 206010019851 Hepatotoxicity Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000611 antibody drug conjugate Substances 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000000445 cytocidal effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 230000007686 hepatotoxicity Effects 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229940051022 radioimmunoconjugate Drugs 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012536 storage buffer Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MRYQZMHVZZSQRT-UHFFFAOYSA-M tetramethylazanium;acetate Chemical compound CC([O-])=O.C[N+](C)(C)C MRYQZMHVZZSQRT-UHFFFAOYSA-M 0.000 description 3
- 125000000101 thioether group Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 2
- HTJMXYRLEDBSLT-UHFFFAOYSA-N 1,2,4,5-tetrazine Chemical compound C1=NN=CN=N1 HTJMXYRLEDBSLT-UHFFFAOYSA-N 0.000 description 2
- NVFSHTYUVXEYKP-UHFFFAOYSA-N 1,4,7,10-tetrakis(pyridin-2-ylmethyl)-1,4,7,10-tetrazacyclododecane Chemical compound C=1C=CC=NC=1CN(CCN(CC=1N=CC=CC=1)CCN(CC=1N=CC=CC=1)CC1)CCN1CC1=CC=CC=N1 NVFSHTYUVXEYKP-UHFFFAOYSA-N 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
- RAEOEMDZDMCHJA-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O RAEOEMDZDMCHJA-UHFFFAOYSA-N 0.000 description 2
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical class OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 description 2
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 2
- SYFGLWDDLZQFNI-UHFFFAOYSA-N 2-[4-(carboxymethyl)-1,4,8,11-tetrazabicyclo[6.6.2]hexadecan-11-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCCN2CCN(CC(=O)O)CCCN1CC2 SYFGLWDDLZQFNI-UHFFFAOYSA-N 0.000 description 2
- RZESKRXOCXWCFX-UHFFFAOYSA-N 2-[bis[2-[carboxymethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid Chemical compound CNC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NC RZESKRXOCXWCFX-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- JVHROZDXPAUZFK-UHFFFAOYSA-N TETA Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CCCN(CC(O)=O)CC1 JVHROZDXPAUZFK-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 230000005260 alpha ray Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000005250 beta ray Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960000958 deferoxamine Drugs 0.000 description 2
- ILKCDNKCNSNFMP-UHFFFAOYSA-N dimethyl octanediimidate;hydron;dichloride Chemical compound Cl.Cl.COC(=N)CCCCCCC(=N)OC ILKCDNKCNSNFMP-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 125000002228 disulfide group Chemical group 0.000 description 2
- BJAJDJDODCWPNS-UHFFFAOYSA-N dotp Chemical compound O=C1N2CCOC2=NC2=C1SC=C2 BJAJDJDODCWPNS-UHFFFAOYSA-N 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 229960005219 gentisic acid Drugs 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
- LUEAPCWNZXBITO-UHFFFAOYSA-N 1,4-dibenzylcyclooct-2-yn-1-amine Chemical compound C1CCCC(CC=2C=CC=CC=2)C#CC1(N)CC1=CC=CC=C1 LUEAPCWNZXBITO-UHFFFAOYSA-N 0.000 description 1
- KUWKQASGHNTJAT-UHFFFAOYSA-N 1-hydroxy-n-[3-[(1-hydroxy-6-oxopyridine-2-carbonyl)-[4-[(1-hydroxy-6-oxopyridine-2-carbonyl)-[3-[(1-hydroxy-6-oxopyridine-2-carbonyl)amino]propyl]amino]butyl]amino]propyl]-6-oxopyridine-2-carboxamide Chemical compound C1=CC(=O)N(O)C(C(=O)NCCCN(CCCCN(CCCNC(=O)C=2N(C(=O)C=CC=2)O)C(=O)C=2N(C(=O)C=CC=2)O)C(=O)C=2N(C(=O)C=CC=2)O)=C1 KUWKQASGHNTJAT-UHFFFAOYSA-N 0.000 description 1
- YSFQIJDACSFIOH-UHFFFAOYSA-N 2,2-diaminopropanoic acid Chemical group CC(N)(N)C(O)=O YSFQIJDACSFIOH-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- AOBBBGYEGNXRPX-QWHCGFSZSA-N 2-[2-[[(1s,2r)-2-[bis(carboxymethyl)amino]cyclohexyl]-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)[C@H]1CCCC[C@H]1N(CC(O)=O)CC(O)=O AOBBBGYEGNXRPX-QWHCGFSZSA-N 0.000 description 1
- GTACSIONMHMRPD-UHFFFAOYSA-N 2-[4-[2-(benzenesulfonamido)ethylsulfanyl]-2,6-difluorophenoxy]acetamide Chemical compound C1=C(F)C(OCC(=O)N)=C(F)C=C1SCCNS(=O)(=O)C1=CC=CC=C1 GTACSIONMHMRPD-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- SKPBWRIBVVBTRG-UHFFFAOYSA-N 3,3-dibenzylcyclooctyne pyrrole-2,5-dione Chemical compound O=C1NC(=O)C=C1.C(c1ccccc1)C1(Cc2ccccc2)CCCCCC#C1 SKPBWRIBVVBTRG-UHFFFAOYSA-N 0.000 description 1
- AEZNJDZKJCAEMS-UHFFFAOYSA-N 3-[(2,5-dioxopyrrolidin-3-yl)disulfanyl]pyrrolidine-2,5-dione Chemical compound O=C1NC(=O)CC1SSC1C(=O)NC(=O)C1 AEZNJDZKJCAEMS-UHFFFAOYSA-N 0.000 description 1
- AQWXHYUWFUXFFH-UHFFFAOYSA-N 3-[4,7,10-tris(2-carboxyethyl)-1,4,7,10-tetrazacyclododec-1-yl]propanoic acid Chemical compound OC(=O)CCN1CCN(CCC(O)=O)CCN(CCC(O)=O)CCN(CCC(O)=O)CC1 AQWXHYUWFUXFFH-UHFFFAOYSA-N 0.000 description 1
- SOUJYUTZZAWCOV-UHFFFAOYSA-N 3-[4,8,11-tris(2-carboxyethyl)-1,4,8,11-tetrazacyclotetradec-1-yl]propanoic acid Chemical compound OC(=O)CCN1CCCN(CCC(O)=O)CCN(CCC(O)=O)CCCN(CCC(O)=O)CC1 SOUJYUTZZAWCOV-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- RNTXYZIABJIFKQ-UHFFFAOYSA-N 4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCCCCCCCCCCCSC(=S)SC(C)(C#N)CCC(O)=O RNTXYZIABJIFKQ-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101710130081 Aspergillopepsin-1 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102100031007 Cytosolic non-specific dipeptidase Human genes 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- QEVGZEDELICMKH-UHFFFAOYSA-N Diglycolic acid Chemical compound OC(=O)COCC(O)=O QEVGZEDELICMKH-UHFFFAOYSA-N 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- DHYBHKGEMCSEDY-UHFFFAOYSA-N OC1C2(C(N(C(C1(CN(C2)CC1=CC=CC(=N1)C(=O)O)C(=O)OC)C1=NC=CC=C1)CC1=CC=CC(=N1)C(=O)O)C1=NC=CC=C1)C(=O)OC Chemical compound OC1C2(C(N(C(C1(CN(C2)CC1=CC=CC(=N1)C(=O)O)C(=O)OC)C1=NC=CC=C1)CC1=CC=CC(=N1)C(=O)O)C1=NC=CC=C1)C(=O)OC DHYBHKGEMCSEDY-UHFFFAOYSA-N 0.000 description 1
- LDCHYBFLHSZQKG-UHFFFAOYSA-N OCCCN1NNCCCCCCCC(CC(O)=O)(CC(O)=O)N1CC(O)=O Chemical compound OCCCN1NNCCCCCCCC(CC(O)=O)(CC(O)=O)N1CC(O)=O LDCHYBFLHSZQKG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- INJRKJPEYSAMPD-UHFFFAOYSA-N aluminum;silicic acid;hydrate Chemical compound O.[Al].[Al].O[Si](O)(O)O INJRKJPEYSAMPD-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- LNENVNGQOUBOIX-UHFFFAOYSA-N azidosilane Chemical compound [SiH3]N=[N+]=[N-] LNENVNGQOUBOIX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- NIRLBCOFKPVQLM-UHFFFAOYSA-N dbco-c6-acid Chemical compound OC(=O)CCCCC(=O)N1CC2=CC=CC=C2C#CC2=CC=CC=C12 NIRLBCOFKPVQLM-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 239000012969 di-tertiary-butyl peroxide Substances 0.000 description 1
- 229940127043 diagnostic radiopharmaceutical Drugs 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical group OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- LRHXBHUTQWIZTN-UHFFFAOYSA-N dimethyl heptanediimidate;dihydrochloride Chemical compound Cl.Cl.COC(=N)CCCCCC(=N)OC LRHXBHUTQWIZTN-UHFFFAOYSA-N 0.000 description 1
- LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- UCSVJZQSZZAKLD-UHFFFAOYSA-N ethyl azide Chemical compound CCN=[N+]=[N-] UCSVJZQSZZAKLD-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- MBAXWTVHCRPVFW-UHFFFAOYSA-N methyl 3-[(3-imino-3-methoxypropyl)disulfanyl]propanimidate Chemical compound COC(=N)CCSSCCC(=N)OC MBAXWTVHCRPVFW-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100001092 no hepatotoxicity Toxicity 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- IBZUISWMZGLPKG-UHFFFAOYSA-N phosphoric acid azide Chemical compound [N-]=[N+]=[N-].OP(O)(O)=O IBZUISWMZGLPKG-UHFFFAOYSA-N 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- HSVFKFNNMLUVEY-UHFFFAOYSA-N sulfuryl diazide Chemical compound [N-]=[N+]=NS(=O)(=O)N=[N+]=[N-] HSVFKFNNMLUVEY-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000004905 tetrazines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Definitions
- the present invention relates to anti-EGFR antibody radioconjugates and radiopharmaceuticals.
- EGFR Extracellular Growth Factor Receptor
- HER1, ErbB1 EGFR (Epidermal Growth Factor Receptor) is a tyrosine kinase-type receptor that recognizes and signals growth factors that control cell proliferation and growth. It is a transmembrane protein with a molecular weight of about 170 kDa. is. Also called HER1, ErbB1.
- Cetuximab is known as an anti-EGFR antibody. Cetuximab is a monoclonal antibody that inhibits the function of EGFR, is used as an anticancer agent, and is one of molecular-targeted therapeutic agents that target specific molecules involved in cancer growth and the like.
- Cetuximab is known to be an antibody used in marketed ADCs (Antibody Drug Conjugates).
- ADCs using cetuximab include drugs in which a payload (drug), which is a chemotherapeutic agent or a photosensitizer, is covalently bound to an antibody via a linker.
- Antibody drugs have high target selectivity and relatively few side effects, but their efficacy may be insufficient.
- One type of payload, chemotherapeutic agents has strong efficacy but low target selectivity, so the minimum effective dose required to kill cancer cells is high. Since it cannot be increased much, the maximum tolerated dose is low and the therapeutic dose range is narrow. According to ADC, it becomes possible to selectively deliver more chemotherapeutic agents to cancer cells, and as a result, less chemotherapeutic agents reach normal cells. It is expected that the therapeutic dose range will be widened by increasing the maximum tolerated dose.
- radioimmunoconjugate In radioimmunoconjugates, radionuclides are used instead of payloads.
- Patent Document 1 describes two A radiopharmaceutical composition is described in which cetuximab is modified with radioactive copper using a functional chelating agent.
- radioimmunoconjugates that use radionuclides that emit gamma rays or positrons as radionuclides can be used for nuclear medicine examinations.
- Patent Document 2 describes that cetuximab can be modified by introducing DTPA into a peptide that site-specifically modifies the Fc region of an antibody, and labeled with a radiometal nuclide.
- Patent Document 1 does not describe site-specific modification of anti-EGFR antibodies with peptides. In addition, there is no disclosure or suggestion regarding the problem of anti-EGFR antibodies forming thiourea bonds.
- One aspect of the present invention is a conjugate of an anti-EGFR antibody site-specifically modified with a peptide and a chelating agent, wherein the chelating agent is chelated with a radiometal nuclide, and the peptide and the chelating agent are linked by a linker ( L), and the linker (L) is a conjugate that does not contain a thiourea bond.
- Another aspect of the present invention is a radiopharmaceutical containing the above complex as an active ingredient.
- another aspect of the present invention contains a chelating agent in which a radiometal nuclide is chelated and a complex of an anti-EGFR antibody as an active ingredient, and does not contain a thiourea bond in the linkage between the anti-EGFR antibody and the chelating agent.
- a radiopharmaceutical in which the radiochemical purity of the conjugate is 90% or more when stored at room temperature for 7 days.
- connection means both direct and indirect connection, unless otherwise specified.
- a radioconjugate of an anti-EGFR antibody with improved stability compared to conventional ones is provided without impairing its efficacy.
- FIG. 1 is a graph showing the results of evaluating the antigen-binding properties of radioactive complexes produced according to the descriptions of Example 1 and Comparative Example 1.
- FIG. The vertical axis is the value obtained by dividing the count value in the region of interest (ROI) set on the tumor section used by the area of the ROI, and the value obtained by dividing the count value of the standard radiation source by the area of the standard radiation source.
- the horizontal axis indicates the cell type of the tumor section used for evaluation.
- FIG. 4 is a diagram showing a representative example of a PET image (MIP image) of a radioconjugate produced according to Example 2 in a tumor-bearing mouse.
- FIG. 10 is a diagram showing a representative example of a PET image (MIP image) of a radioconjugate produced according to Comparative Example 2 in a tumor-bearing mouse. Arrows indicate tumors derived from tumor-bearing A431 cells.
- 1 is a graph showing changes in tumor volume over time in tumor-bearing mice of a radioconjugate (Example 1)-administered group, a radioconjugate (Comparative Example 1)-administered group, an antibody control group, and a vehicle group.
- the vertical axis represents the relative value when the tumor volume at the time of administration of each drug is set to 1, and the horizontal axis represents the number of days elapsed since administration of each drug.
- the graph represents the mean ⁇ standard deviation of the tumor volume of each group. " ⁇ ” indicates the time point at which a significant difference (p ⁇ 0.05) was observed from the vehicle group (p ⁇ 0.01).
- 1 is a graph showing changes in body weight over time in tumor-bearing mice of a radioconjugate (Example 1)-administered group, a radioconjugate (Comparative Example 1)-administered group, an antibody control group, and a vehicle group.
- the vertical axis indicates the relative value when the body weight at the time of administration of each drug is set to 1, and the horizontal axis indicates the number of days elapsed since administration of each drug.
- the graph represents the mean ⁇ standard deviation of the body weight of each group.
- FIG. 10 is a graph showing the results of evaluating the specificity of the radioconjugates produced according to the description of Example 6 to EGFR.
- FIG. The vertical axis indicates the value obtained by dividing the count value in the ROI set on the tumor section used by the area of the ROI, and the value obtained by dividing the count value of the standard radiation source by the area of the standard radiation source.
- the horizontal axis indicates the cell type of the tumor section used for evaluation.
- FIG. 10 is a graph showing the cell-killing effect of 225 Ac complex-labeled panitumumab on COLO205 cells (top) and HCT-116 cells (bottom). Unlabeled panitumumab was added as a control.
- the vertical axis represents the relative value when the number of viable cells in the condition where no antibody was added was set to 1, and the horizontal axis represents the concentration of the added antibody.
- the graph represents the mean ⁇ standard deviation of each group.
- the vertical axis represents the relative value when the number of viable cells in the condition where no antibody was added was set to 1, and the horizontal axis represents the concentration of the added antibody.
- the graph represents the mean ⁇ standard deviation of each group.
- FIG. 10 is a graph showing the cytocidal effect of 225 Ac complex-labeled panitumumab on NCI-H358 cells.
- FIG. Unlabeled panitumumab was added as a control.
- the vertical axis represents the relative value when the number of viable cells in the condition where no antibody was added was set to 1, and the horizontal axis represents the concentration of the added antibody.
- the graph represents the mean ⁇ standard deviation of each group. Fig.
- FIG. 3 is a graph showing the ability of 225 Ac complex-labeled panitumumab to induce apoptosis in COLO205 cells and SW48 cells. Unlabeled panitumumab was added as a control. The vertical axis represents the relative value when the caspase-3/7 activity in the condition where no antibody was added was set to 1, and the horizontal axis represents the concentration of the added antibody. The graph represents the mean ⁇ standard deviation of each group.
- FIG. 4 shows the DNA double-strand break effect of 225 Ac complex-labeled panitumumab on SW48 cells. Cell nuclei were stained and detected with DAPI (upper images), and ⁇ H2AX was stained and detected (lower images). FIG.
- FIG. 4 shows the DNA double-strand break effect of 225 Ac complex-labeled panitumumab on MIAPaCa-2 cells. Cell nuclei were stained and detected with DAPI (upper images), and ⁇ H2AX was stained and detected (lower images). FIG. 4 shows the DNA double-strand break effect of 225 Ac complex-labeled panitumumab on NCI-H358 cells. Cell nuclei were stained and detected with DAPI (upper images), and ⁇ H2AX was stained and detected (lower images).
- Radioconjugate (Example 6) high radioactivity administration group, radioconjugate (Example 6) low radioactivity administration group, antibody intraperitoneal administration group, antibody control group and vehicle group tumor-bearing mice (COLO205 cells) over time 2 is a graph showing changes in tumor volume.
- the vertical axis represents the average tumor volume in each group, and the horizontal axis represents the number of days elapsed since administration of each drug.
- the graph represents the mean ⁇ standard deviation of the tumor volume of each group. " ⁇ ” indicates the time point at which a significant difference (p ⁇ 0.05) was observed from the vehicle group, and " ⁇ " indicates the time point at which a significant difference (p ⁇ 0.05) was observed in the antibody intraperitoneal administration group.
- Radioconjugate (Example 6) high radioactivity administration group, radioconjugate (Example 6) low radioactivity administration group, antibody intraperitoneal administration group, antibody control group and vehicle group in tumor-bearing mice (HCT-116 cells) 1 is a graph showing changes in tumor volume over time.
- the vertical axis represents the average tumor volume in each group, and the horizontal axis represents the number of days elapsed since administration of each drug.
- the graph represents the mean value ⁇ standard deviation of the tumor volume of each group, "**" is the time point when a significant difference (p ⁇ 0.01) was observed from the antibody control group, and " ⁇ " is from the vehicle group.
- Radioconjugate (Example 6) Shown are the time points at which a significant difference (p ⁇ 0.05) was observed from the high radioactivity administration group.
- Tumor-bearing mice (SW48 cells) over time 2 is a graph showing changes in tumor volume.
- the vertical axis represents the average tumor volume in each group, and the horizontal axis represents the number of days elapsed since administration of each drug.
- the graph represents the mean value ⁇ standard deviation of the tumor volume of each group, "**" is the time point when a significant difference (p ⁇ 0.01) was observed from the antibody control group, and " ⁇ ” is from the vehicle group. indicates the time points at which a significant difference (p ⁇ 0.01) was observed.
- Fig. 4 is a graph showing changes in tumor volume over time in COLO205 tumor-bearing mice in a radioconjugate (Example 6)-administered group, an oxaliplatin-administered group, and a vehicle group.
- the measurement results of hepatotoxicity (upper and middle figures) and nephrotoxicity (lower figure) markers are shown.
- FIG. 4 is a diagram showing representative examples of PET images (MIP images) in COLO205 cell tumor-bearing mice to which a radioconjugate prepared according to the description of Example 2 was administered.
- Radioactive conjugate is a conjugate of an anti-EGFR antibody site-specifically modified with a peptide and a chelating agent, wherein the chelating agent is chelated with a radioactive metal nuclide, and the peptide and the chelating agent is linked via a linker (L), and the linker (L) does not contain a thiourea bond.
- Radiometal nuclide contained in the radioactive complex of the present invention is an ⁇ -ray-emitting radionuclide, a ⁇ -ray-emitting radionuclide, a positron-emitting radionuclide, or a ⁇ -ray-emitting radionuclide. It is a radionuclide.
- the radioconjugate of the present invention is used for cancer therapy, it is preferable to use an ⁇ -ray-emitting radionuclide or a ⁇ -ray-emitting radionuclide.
- radioconjugate of the present invention When the radioconjugate of the present invention is used for cancer diagnosis or detection, it is preferable to use a positron-emitting radionuclide or a ⁇ -ray-emitting radionuclide.
- Bi-212, Bi-213, Ac-225, and Th-227 are exemplified as radionuclides that emit alpha rays.
- Cu-64, Y-90 or Lu-177 are exemplified as radionuclides that emit ⁇ rays. Examples of radionuclides that emit positrons include Cu-64, Ga-68, Y-86, and Zr-89.
- Tc-99m or In-111 is exemplified as a radionuclide that emits gamma rays.
- the radiometal nuclide contained in the radioconjugate of the present invention is more preferably Ga-68, Zr-89, Y-90, In-111, Lu-177 or Ac-225, Zr-89, Y-90, Lu -177 or Ac-225 are more preferred.
- the antibody contained in the radioconjugate of the present invention is an immunoglobulin that specifically binds to EGFR (hereinafter also referred to as the antibody used in the present invention).
- the antibodies used in the present invention may be polyclonal antibodies or monoclonal antibodies, preferably monoclonal antibodies.
- the origin of the antibody is not particularly limited, but examples include non-human animal antibodies, non-human mammal antibodies, and human antibodies, preferably human, rat, mouse, and rabbit antibodies.
- Antibodies derived from species other than humans are preferably chimerized or humanized using well-known techniques, but the antibodies used in the present invention may be chimeric antibodies, humanized antibodies, or human antibodies.
- may Antibodies used in the present invention may also be bispecific antibodies.
- Antibodies used in the invention are, for example, IgG, and can be, for example, IgG1, IgG2 (eg, IgG2a and IgG2b), IgG3, or IgG4.
- the antibody used in the radioconjugate of the present invention is cetuximab or panitumumab.
- Cetuximab is an IgG 1 subclass human-mouse chimerized monoclonal antibody that specifically recognizes EGFR, and by inhibiting EGFR activation and dimerization, colorectal cancer, head and neck cancer, It is known to have a tumor growth inhibitory effect on non-small cell lung cancer, gastric cancer and the like.
- cetuximab is an antibody described in JP-A-2005-047934, specifically, Light chain amino acid sequence (SEQ ID NO: 1):
- Cetuximab is clinically used as an anti-tumor agent indicated for RAS gene wild-type unresectable advanced/recurrent colorectal cancer, head and neck cancer, and is known as Erbitux (registered trademark). Available.
- Panitumumab is a human IgG2 monoclonal antibody that specifically recognizes EGFR. Its chemical name (nomenclature) is derived from 214 amino acid residues (C 1028 H 1588 N 274 O 336 S 6 ; molecular weight: 23,353.63 ) and two heavy chain molecules consisting of 445 amino acid residues ( C2171H3355N573O672S18 ; molecular weight: 48,811.47 ). It is a constitutive glycoprotein (molecular weight: ca. 147,000) and the major component of the heavy chain subunit lacks a C-terminal lysine.
- the amino acid sequence of panitumumab is shown as follows in the review report by the Pharmaceuticals and Medical Devices Agency for Vectibix Intravenous Infusion 100 mg "Takeda Bio”. Light chain (SEQ ID NO:3):
- intramolecular disulfide bonds are indicated by solid lines.
- An intermolecular disulfide bond is formed between the heavy chain Cys222 residue and the light chain Cys214 residue, between the heavy chain Cys225 residues, and between the heavy chain Cys228 residues.
- the underlined Asn ( Asn ) is the sugar chain binding position, and the asterisked Gln (Gln * ) is partially cyclized to pyroglutamic acid. Lys with double asterisks (Lys ** ) is almost completely absent.
- the carbohydrate structure is shown below.
- Fuc is L-fucose
- (Gal)0-2 is 0, 1 or 2 molecules of D-galactose
- GlucNac is DN-acetylglucosamine
- Man is D-mannose.
- Panitumumab is clinically used as an anti-tumor agent for KRAS wild-type, unresectable, advanced or recurrent colorectal cancer, and is available as Vectibix (registered trademark). is.
- the chelating agent is not particularly limited as long as it has a site in its structure to which a radiometal nuclide is coordinated.
- Chelating agents such as CB-TE2A (1,4,8,11-Tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid), CDTA (Cyclohexane-trans-1,2-diamine tetra-acetic acid) , CDTPA (4-cyano-4-[[(dodecylthio)thioxomethyl]thio]-pentanoic acid), DOTA (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid), DOTMA (( 1R,4R,7R,10R)- ⁇ , ⁇ ', ⁇ ′′, ⁇ ′′′-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), DOTMA (( 1
- R 11 , R 12 , R 13 and R 14 are each independently —(CH 2 ) p COOH, —(CH 2 ) p C 5 H 5 N, —(CH 2 ) a group consisting of p PO 3 H 2 , —(CH 2 ) p CONH 2 or —(CHCOOH)(CH 2 ) p COOH, R 15 is a hydrogen atom, and p is an integer of 0 or more and 3 or less; be.
- the compound represented by formula (A) preferably includes a structure derived from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or a derivative thereof.
- DOTA 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
- DOTMA ((1R,4R,7R,10R)- ⁇ , ⁇ ', ⁇ ”, ⁇ '”-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)
- DOTAM (1,4,7,10-tetrakis(carbamoylmethyl)-1 ,4,7,10-tetraazacyclododecane
- DOTPA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrapropionic acid), 1,4,7,10-tetrakis(pyr
- the chelating agent used is DOTA-GA
- the chelating agent may be a stereoisomer (S-isomer, R-isomer) or a racemate. It may be a mixture of S-stereoisomers and R-stereoisomers in any ratio.
- a chelating agent used in the present invention is linked to a peptide via a linker (L).
- the chelating agent and the linker (L) are connected by a covalent bond. Therefore, in the radioconjugate of the present invention, some groups in the compound of the aforementioned chelating agent may be substituted with groups that form covalent bonds with the linker (L).
- R 12 or R 15 may be substituted with a group that forms a covalent bond with the linker (L).
- R 15 is a hydrogen atom when R 12 is substituted with a group that forms a covalent bond with the linker (L), and R 12 is —(CH 2 ) p COOH, —(CH 2 ) p C 5 H 5 N, —(CH 2 ) p PO 3 H 2 , —(CH 2 ) p CONH 2 or —(CHCOOH)(CH 2 ) p COOH, when R 15 is a linker (L) and It is substituted with a group that forms a covalent bond.
- the covalent bond between the chelating agent and the linker (L) does not have to contain a thiourea bond, and includes carbon-carbon bonds, amide bonds, ether bonds, ester bonds and the like.
- connection between the chelating agent and the linker (L) is, for example, an N-hydroxysuccinimide ester (NHS) group of formula (A-7) or (A-8) below, or 2, of formula (A-9) below.
- NHS N-hydroxysuccinimide ester
- the peptide modifies the antibody site-specifically, preferably the Fc region site-specifically, more preferably the lysine residue in the Fc region of the antibody site-specifically. If so, it is not particularly limited. As a result, the activity of the antibody itself (antigen recognition action, neutralization action, complement activation action and/or opsonization action) can be maintained.
- the peptide used in the present invention may be a chain peptide or a cyclic peptide, but a cyclic peptide is preferred. More preferably, it contains an amino acid sequence consisting of 13 or more and 17 or less amino acid residues represented by the following formula (i) (hereinafter also referred to as "antibody-modified peptide") and is modified with a cross-linking agent.
- formula (i) the left side of the amino acid sequence on the page indicates the N-terminal side, and the right side of the amino acid sequence on the page indicates the C-terminal side.
- Xa, Xb, Xc and Xd each represent a consecutive number of X, b consecutive number of X, c consecutive number of X, and d consecutive number of X;
- X is an amino acid residue having neither a thiol group nor a haloacetyl group in its side chain;
- a, b, c and d are each independently an integer of 1 or more and 5 or less and satisfy a+b+c+d ⁇ 14, and
- Xaa1 and Xaa3 are each independently Represents an amino acid residue derived from an amino acid having a thiol group in the side chain, or an amino acid residue derived from an amino acid having a haloacetyl group in the side chain, provided that either one of Xaa1 and Xaa3 is an amino acid having a thiol
- Amino acid residues that can be included in X in the above formula (i) include, for example, glycine, alanine, phenylalanine, proline, asparagine, aspartic acid, glutamic acid, arginine, histidine, serine, threonine, tyrosine, derived from amino acids such as methionine.
- X may be an amino acid residue consisting of the same type of amino acid, or an amino acid residue consisting of different types of amino acids.
- a, b, c and d in formula (i) are not particularly limited as long as they are numbers within the ranges described above.
- a is preferably an integer of 1 or more and 3 or less
- b is preferably an integer of 1 or more and 3 or less
- c is preferably an integer of 3 or more and 5 or less
- d is preferably an integer of 1 or more and 3 or less.
- At least one of Xaa1 and Xaa3 is an amino acid residue derived from an amino acid having a thiol group in its side chain, and the amino acids may be the same or different.
- amino acids having a thiol group in their side chains include cysteine and homocysteine.
- Such amino acid residues are preferably linked by a disulfide bond or linked by a sulfide group via the structure shown in formula (4) below.
- the wavy line portion indicates the bonding portion with the sulfide group.
- Xaa1 and Xaa3 are, in place of the above combinations, one of Xaa1 and Xaa3 an amino acid residue derived from an amino acid having a thiol group in the side chain, and the other an amino acid derived from an amino acid having a haloacetyl group in the side chain It may be a residue. They are linked via a thioether bond. A haloacetyl group is terminated with a halogen such as iodine, and reacts with a thiol group on the other side chain to eliminate the halogen and form a thioether bond.
- a halogen such as iodine
- antibody-modified peptides represented by formula (i) include, for example, peptides described in WO2016/186206, WO2017/217347 and WO2018/230257. , these can also be used.
- the antibody-modified peptide used in the present invention is an amino acid sequence consisting of 13 to 17 amino acid residues represented by the following formula (i)'. (X 1-3 )-C-(Xaa3′)-(Xaa4′)-H-(Xaa1′)-G-(Xaa2′)-LVWC-(X 1-3 ) (i)′
- each of X is independently any amino acid residue other than cysteine;
- C is a cysteine residue, H is a histidine residue,
- Xaa1' is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid;
- G is a glycine residue,
- Xaa2' is a glutamic acid residue or an asparagine residue,
- L is a leucine residue,
- V is a valine residue,
- W is a tryptophan residue,
- Xaa3' is an alanine, serine or threonine residue and
- Xaa4' is a tyrosine or tryptophan residue.
- the notation X 1-3 at the N-terminus or C-terminus means that 1 to 3 consecutive amino acid residues X independently of cysteine (C or Cys) It means that the amino acid residues constituting it are the same or different residues, but preferably consist of a sequence in which all three are not the same residues.
- the amino acid sequence of the antibody-modified peptide preferably has any one of the following sequences (1) to (14), and the following sequences (1), (2), and (13) or (14) is more preferred.
- (Xaa2) is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, preferably a lysine residue preferably (Xaa2) is modified with a cross-linking agent, and (Xaa1) and (Xaa3) both represent homocysteine residues.
- amino acids other than (Xaa1), (Xaa2) and (Xaa3) are represented by single-letter abbreviations.
- the peptide represented by the above formula (i) or (i)' or the peptide having the sequences (1) to (14) preferably has a linker (L) introduced at the N-terminus and is amidated at the C-terminus. be done.
- Xaa2 (or the Xaa2 equivalent) of these peptides is modified with a cross-linking agent, which allows the peptide to covalently bind to the Fc region of an anti-EGFR antibody via the cross-linking agent.
- the portion corresponding to Xaa2 is Xaa1'.
- a cross-linking agent can be appropriately selected by those skilled in the art, and binds to desired amino acids (e.g., lysine, cysteine, aspartic acid, glutamic acid, 2-aminosuberic acid, diaminopropionic acid, arginine, etc.).
- desired amino acids e.g., lysine, cysteine, aspartic acid, glutamic acid, 2-aminosuberic acid, diaminopropionic acid, arginine, etc.
- a compound can have at least two possible sites.
- Examples include, but are not limited to, cross-linking agents preferably containing two or more succinimidyl groups such as DSG (disuccinimidyl glutarate), DSS (disuccinimidyl suberate), DMA (dimethyl adipimidate 2HCl, dimethyl adipimidate dihydrochloride), DMP (dimethyl pimelimidate 2HCl, dimethyl pimelimidate dihydrochloride), and DMS (dimethyl suberimidate 2HCl, dimethyl suberimidate dihydrochloride).
- DSG disuccinimidyl glutarate
- DSS disuccinimidyl suberate
- DMA dimethyl adipimidate 2HCl, dimethyl adipimidate dihydrochloride
- DMP dimethyl pimelimidate 2HCl, dimethyl pimelimidate dihydrochloride
- DMS dimethyl suberimidate 2HCl, dimethyl suberimidate dihydrochloride
- Cross-linking agents preferably containing two or more, and DTBP (dimethyl 3,3'-dithiobispropionimidate 2HCl, 3,3'-dithiobispropionimidic acid dimethyl dihydrochloride) and DSP (dithiobis (succinimidyl propionate), dithiobissuccinimide SBAP (succinimidyl 3-(bromoacetamide) propionate) and SBAP (succinimidyl 3-(bromoacetamide) propionate).
- a cross-linking agent containing a succinimidyl group such as DSS or DSG reacts with a primary amine present at the N-terminus.
- a linker may be previously introduced to the N-terminus of the antibody-modified peptide and then reacted with DSS or DSG.
- the succinimidyl group of DSS or DSG as an anti-EGFR antibody, e.g.
- An anti-EGFR antibody is site-specifically modified with a peptide, preferably by reacting with the Lys246 residue.
- Lys residues are present in the Fc region of human IgG, and even for anti-EGFR antibodies other than cetuximab, those skilled in the art can align the amino acid sequences of the antibodies and identify the corresponding Lys residues. .
- Linker (L) is not particularly limited as long as it can link the chelating agent and the peptide in the radioconjugate of the present invention.
- the linker (L) used in the present invention is not particularly limited as long as it does not contain a thiourea bond, and may include substituted or unsubstituted alkyl groups, substituted or unsubstituted heteroalkyl groups, polyethylene glycol (PEG) groups, peptides, Examples include sugar chains, disulfide groups, amide groups, and combinations thereof.
- the linker (L) is a general term for linkers used to connect a peptide-modified anti-EGFR antibody and a chelating agent, including antibody-modified linkers (L 1 ) and chelate linkers (L 2 ). terminology.
- the antibody-modified linker (L 1 ) which will be described in detail later, is introduced to the N-terminal side of the peptide described in (1-4), and the chelate linker (L 2 ) will also be described in detail later. It is introduced into the functional group of the chelating agent described in (1-3).
- the linker (L) used in the present invention may contain a binding site formed by a click reaction.
- the antibody-modified linker (L 1 ) and the chelate linker (L 2 ) are bound by a click reaction. ing.
- the chelate linker ( L2) does not contain a thiourea bond.
- the binding site formed by the click reaction is preferably a triazole skeleton-containing structure represented by the following formula (10a) or (10b) or a pyridazine skeleton-containing structure represented by the following formula (10c). . Since Formula (10a) and Formula (10b) are in an isomer relationship, they may be contained in an arbitrary ratio.
- R1A represents the linking site with the chelating agent
- R2A represents the linking site with the antibody-modified peptide
- one of R 3A and R 4A represents a hydrogen atom, a methyl group, a phenyl group or a pyridyl group, the other represents a linking site with a chelating agent
- R 5A is a linking site with an antibody-modified peptide.
- the peptide is linked via an antibody-modified linker (L 1 ) to the antibody-modified peptide linking site, and the chelating agent linking site is A chelating agent is linked via a chelate linker (L 2 ).
- the antibody is site-specifically modified with a peptide, and the peptide and the chelating agent are linked via a linker (L). It is a complex of chelating agents.
- the method for producing a radioactive conjugate of the present invention comprises a conjugation step of conjugating a chelating agent and an anti-EGFR antibody, and a complex forming a complex between a radiometal nuclide and a chelating agent. It can be manufactured from two steps: a forming step.
- the conjugation step may be before the complex formation step or after the complex formation step.
- the Fc region of the antibody is site-specifically modified with the chelating agent or linker (L) having the antibody-modified peptide represented by formula (i) above.
- the chelating agent is allowed to chelate (complex) the radiometal nuclide.
- the radiometal nuclide used here is preferably used in an ionizable form, more preferably in an ionic form.
- the order of addition of the radiometal nuclide to the chelating agent does not matter as long as complex formation with the radiometal nuclide is possible.
- a solution in which radioactive metal ions are dissolved in a solvent mainly composed of water can be used as a radionuclide.
- the resulting complex may be purified using filtration filters, membrane filters, columns packed with various packing materials, chromatography, and the like.
- the conjugation step is preferably performed after the complex formation step.
- a complex is formed between a radiometal nuclide and a chelating agent having a click-reactive first atomic group as a substituent for enabling conjugation with an antibody.
- the conjugation step (B) the antibody-modified linker (L 1 ) having the antibody-modified peptide represented by the above formula (i) and a click-reactive second atomic group is used to site-specifically convert the Fc region and the complexed chelating agent obtained in step (A) to obtain the radioconjugate of the present invention.
- the steps (A) and (B) are described in detail below.
- the combination of the first atomic group and the second atomic group capable of a click reaction an appropriate one is selected according to the type of click reaction. and an alkene.
- the first atomic group has one of the above combinations of atomic groups
- the second atomic group has one of the above combinations of atomic groups different from the first atomic group.
- the chelate linker (L 2 ) is an alkyne and the antibody modification linker (L 1 ) is an azide, or the chelate linker ( It is preferred that L 2 ) is a 1,2,4,5-tetrazine and the antibody-modified linker (L 1 ) is an alkene.
- Specific examples of the click reaction by such a combination of atomic groups include Huisgen cycloaddition reaction, inverse electron demand type Diels-Alder reaction, and the like.
- DBCO dibenzylcyclooctyne
- Combinations with atomic groups (formula (2b)) containing trans-cyclooctene (TCO) can be mentioned as diatomic alkenes.
- a combination of formula (1a) and formula (2a) is preferred.
- R1 represents the linking site with the chelating agent
- R2 represents the linking site with the antibody-modified peptide
- one of R 3 and R 4 represents the linking site with the chelating agent or the linking site with the antibody-modified peptide, and the other represents a hydrogen atom, a methyl group, a phenyl group or a pyridyl group.
- R 5 is a linking site with the antibody-modified peptide when the atomic group of formula (2b) is linked to the chelating agent, and a chelating agent when the atomic group of formula (2b) is linked to the antibody-modified peptide. shows the linking site with
- DBCO dibenzylcyclooctyne
- various commercially available DBCO reagents can be used. Specifically, for example, DBCO-C6-Acid, Dibenzylcyclooctyne-Amine, Dibenzylcyclooctyne Maleimide, DBCO-PEG acid, DBCO-PEG-Alcohol, DBCO-PEG-amine, DBCO-PEG-NH-Boc, Carboxyrhodamine-PEG-DBCO , Sulforhodamine-PEG-DBCO, TAMRA-PEG-DBCO, DBCO-PEG-Biotin, DBCO-PEG-DBCO, DBCO-PEG-Maleimide, TCO-PEG-DBCO, DBCO-mPEG, etc., but preferably Dibenzyloctyn
- a compound having a structure represented by the following formula (ii) is more preferably used in the complex formation step (A).
- AB-C (ii) In formula (ii), A is the chelating agent described above, and B and C collectively are the chelate linker (L 2 ).
- La and Lb are independently linkers having 1 to 50 carbon atoms including at least an amide bond, t is an integer of 0 to 30, and s is 0 or 1. , * is the binding site with A and ** is the binding site with C.
- C is either an alkyne derivative represented by formula (iic) or a tetrazine derivative represented by formula (iid) below.
- X is CHRk-** or N-**
- Y is CHRk or C ⁇ O
- Rk is independently a hydrogen atom or an alkyl group having 1 to 5 carbon atoms and when X is CHRk-** and Y is CHRk, the Rk moieties may together form a cycloalkyl group
- Rf, Rg, Rh and Ri are independently a hydrogen atom, a halogen atom, or an alkyl group having 1 to 5 carbon atoms, in which Rf and Rg together or Rh and Ri may together form a hydrocarbon ring
- ** represents the bonding site with B
- Rj represents a hydrogen atom, a methyl group, a phenyl group or a pyridyl group.
- R 11 to R 14 are —(CH 2 ) p COOH, p is 1, and R 15 is a binding site to B. or R 11 to R 14 are —(CH 2 ) p COOH, p is 1, R 12 is a binding site (*) to B, and R 15 is a hydrogen atom Either DO3A derivatives or DOTAGA derivatives are more preferred.
- A is the above DOTAGA derivative
- B is a linker with 1 to 50 carbon atoms in which La contains an amide bond, s is 0 or 1, and s is 1 is an integer of 0 or more and 30 or less
- Lb is a linker having 1 or more and 50 or less carbon atoms including an amide bond
- C is an alkyne derivative represented by formula (iic), and )
- X is N-**
- Y is CHRk
- Rk is a hydrogen atom
- Rf and Rg combine to form a benzene ring
- Rh and Ri combine to form benzene
- a DOTAGA-PEGt-DBCO derivative that forms a ring and ** is the binding site for B is preferred. More preferred is DOTAGA-DBCO described below.
- the molar ratio of the chelating agent and the radiometal nuclide is preferably 10/1 or more, more preferably 100/1 or more, even more preferably 500/1 or more, and the upper limit is 10000 as chelate portion/radiometal nuclide. /1 or less, more preferably 8000/1 or less, still more preferably 7000/1 or less, for example, the range of 100/1 or more and 7000/1 or less is preferable, and the range of 500/1 or more and 7000/1 or less is more preferable. is.
- the complex formation reaction is preferably carried out in a solvent.
- solvents include water, physiological saline, sodium acetate buffer, ammonium acetate buffer, phosphate buffer, phosphate buffered saline, trishydroxymethylaminomethane buffer (Tris buffer), 4-( 2-Hydroxyethyl)-1-piperazineethanesulfonic acid buffer (HEPES buffer) or buffers such as tetramethylammonium acetate buffer can be used.
- the liquid volume of the solvent is not particularly limited, but from the viewpoint of practicality in the production process, the lower limit is 0.01 mL or more, preferably 0.1 mL or more, and more preferably 1.0 mL or more at the start of step (A). , More preferably 10 mL or more, still more preferably 100 mL or more, and the upper limit is preferably 1000 mL or less, more preferably 100 mL or less, still more preferably 10 mL or less, and even more preferably 1.0 mL or less. .01 mL or more and 100 mL or less.
- the lower limit of the concentration of the chelating agent in the reaction solution for the complex formation reaction is preferably 0.001 ⁇ mol/L at the start of step (A) independently from the viewpoint of the yield of the desired chelating agent.
- the upper limit is preferably 1000 ⁇ mol/L or less, more preferably 100 ⁇ mol/L or less, More preferably, it is 10 ⁇ mol/L or less, for example, a range of 1 ⁇ mol/L or more and 100 ⁇ mol/L or less.
- the temperature of the complex formation reaction may be, for example, room temperature (25° C.) or may be under heating conditions. , preferably 20°C or higher, more preferably 30°C or higher, still more preferably 35°C or higher, still more preferably 37°C or higher, particularly preferably 45°C or higher, and the upper limit is preferably 150°C or lower, more preferably
- the temperature is 120° C. or lower, more preferably 100° C. or lower, and even more preferably 90° C. or lower.
- the antibody used in step (B) uses an antibody-modified linker (L 2 ) having an antibody-modified peptide represented by formula (i) described above and a click-reactive second atomic group, and uses the above "( 1-2) Antibodies” is a peptide-modified antibody in which the Fc region (constant region) of the anti-EGFR antibody is site-specifically modified.
- Antibody-modified peptides are produced by peptide synthesis methods such as liquid-phase synthesis, solid-phase synthesis, automated peptide synthesis, genetic recombination, and phage display, using a combination of amino acids, whether natural or non-natural. It can be manufactured by providing In synthesizing the peptide, functional groups of amino acids used may be protected as necessary. These can be performed, for example, according to the methods described in WO2017/217347 and WO2018/230257.
- the antibody-modified linker (L 2 ) may be a combination of an antibody-modified peptide and a linker (L 2 ) represented by formula (S1) below.
- *-((L i ) m -Z) k -L ii -AG2 (S1) (Wherein, * indicates the binding site with the N-terminus or C-terminus of the peptide, Li is a polyethylene glycol (PEG) linker moiety ; m is an integer of 1 or more and 50 or less, Z is a second linker moiety that connects (L i ) m and L ii , k is 0 or 1, L ii is the second PEG linker moiety; AG2 is the second atomic group. )
- the structure of Z is not particularly limited as long as it is a linker structure that connects (L i ) m and L ii to each other. be able to.
- the amino acid sequence contained in Z preferably contains a cysteine residue, and is bound to L2 via a thioether group formed by binding the thiol group of the cysteine residue and the maleimide group. more preferred.
- the polyethylene glycol (PEG) linker moiety constituting Lii has a structure represented by the following formula (P2).
- n is an integer, preferably 1 or more and 50 or less, more preferably 1 or more and 20 or less, still more preferably 2 or more and 10 or less, still more preferably 2 or more and 6 or less.
- One end of the structure of the PEG linker portion may be modified with a structure derived from a commercially available PEGylation reagent or a structure derived from a reagent commonly used for PEGylation, and is not particularly limited, for example, diglycol Structures derived from acids or derivatives thereof, maleimides or derivatives thereof are exemplified.
- the method for introducing the second atomic group into the antibody-modified linker (L 2 ) is to obtain an antibody-modified peptide having a desired amino acid sequence by the method described above, and then add the peptide with a solubilizing agent and a reducing agent, and Dissolve in a solution to which an acid has been added as necessary, add an organic solvent solution of an atomic group containing an azide group or trans-cyclooctene (TCO) as a second atomic group to the solution, and stir at room temperature.
- TCO trans-cyclooctene
- an atomic group containing an azide group As the second atomic group, a commercially available azide group introduction reagent is used to directly introduce an azide group to the N-terminus or C-terminus of the peptide according to a conventional method, or An atomic group containing an azide group can be introduced via a linked linker structure.
- the azide group-introducing reagent used include silyl azide, phosphate azide, alkylammonium azide, inorganic azide, sulfonyl azide, PEG azide, and the like.
- TCO when introducing an atomic group containing TCO as the second atomic group, TCO may be introduced directly to the N-terminus or C-terminus of the peptide according to a conventional method using a commercially available click chemistry reagent containing TCO. , or an atomic group containing TCO can be introduced via the linker structure described above.
- a method of obtaining a peptide-modified antibody by binding an antibody-modified peptide and an anti-EGFR antibody is according to the description of WO 2017/217347, for example, the antibody-modified peptide described above, an anti-EGFR antibody, and a cross-linking agent. and optionally the catalyst can be dispersed in a suitable buffer.
- the above-mentioned thing can be used for a crosslinking agent.
- the solution containing the anti-EGFR antibody is treated with an ultrafiltration filter or the like and dispersed in the buffer as necessary. Buffer replacement is performed once or twice. It may be performed one or more times before binding with the antibody-modified peptide.
- the present disclosure relates to a method of producing a conjugate of an antibody-modified peptide and an anti-EGFR antibody, comprising mixing an antibody-modified peptide that has been modified with a cross-linking agent and an anti-EGFR antibody.
- a cross-linking reaction can occur between the antibody-modified peptide modified with the cross-linking agent and the anti-EGFR antibody.
- the cross-linking reaction occurs site-specifically between the Xaa2 amino acid residue of the modified antibody peptide and the Lys248 or Lys250 residue, preferably the Lys250 residue, according to Eu numbering in human IgG Fc.
- panitumumab it can occur site-specifically between the Xaa2 amino acid residue of the antibody-modified peptide and the Lys244 or Lys246 residue, preferably Lys246 residue, according to Eu numbering in human IgG Fc.
- the conditions for the mixing step are not particularly limited as long as the conditions are such that a cross-linking reaction occurs between the antibody-modified peptide and the anti-EGFR antibody.
- a reaction can be carried out by mixing an antibody-modified peptide and an anti-EGFR antibody in an appropriate buffer at room temperature (eg, about 15°C to 30°C).
- the mixing step may be performed by adding an appropriate amount of a catalyst that promotes the cross-linking reaction, if necessary.
- a solvent containing at least water is added to dissolve the anti-EGFR antibody.
- the solvent may be, for example, dimethyl sulfoxide, acetonitrile, physiological saline, or sodium acetate buffer, ammonium acetate buffer, phosphate buffer, phosphate buffered saline, Tris buffer, HEPES buffer. and buffers such as tetramethylammonium acetate buffer or histidine buffer.
- the pH at 25°C is preferably 4.0 or more and 10.0 or less, more preferably 5.5 or more and 8.5 or less, from the viewpoint of antibody stability.
- the concentration of the antibody is preferably 1.0 ⁇ mol/L or more as a lower limit and 1000 ⁇ mol/L or less as an upper limit, and more preferably 500 ⁇ mol/L or less as an upper limit.
- an antibody-modified peptide modified with a cross-linking agent and, if necessary, a catalyst are added, and dispersed at 10° C. or higher and 30° C. or lower.
- the mixing ratio of the antibody-modified peptide and the anti-EGFR antibody in the mixing step is not particularly limited.
- the molar ratio of antibody-modified peptide to anti-EGFR antibody can be, for example, 1:1 to 20:1, preferably 2:1 to 20:1 or 5:1 to 10:1.
- the antibody-modified peptide in the mixing step, can be mixed with the anti-EGFR antibody at a ratio of 0.5 to 2.2, preferably 0.8 to 1.8.
- a ratio of 0.5 to 2.2, preferably 0.8 to 1.8 an antibody in which one molecule of the antibody-modified peptide is bound to one anti-EGFR antibody molecule (hereinafter referred to as "monovalent antibody”) can be efficiently obtained.
- the mixing time (reaction time) in the mixing step is not limited as long as a cross-linking reaction occurs between the antibody-modified peptide and the anti-EGFR antibody, for example, 1 minute to 5 hours, preferably 10 minutes to 2 hours. can do.
- the peptide-modified antibody obtained through the above steps is an antibody in which one antibody-modified peptide molecule is bound to one anti-EGFR antibody molecule (i.e., a monovalent antibody), and an antibody-modified peptide 2 to one anti-EGFR antibody molecule.
- a column filled with a packing material in which a protein such as protein A, protein G, or the antibody-modified peptide described above is bound to a carrier can be used.
- the shape of the carrier of the filler packed in such a column includes gels (e.g., column gels), particles, beads, nanoparticles, microparticles, macrobeads, and the like.
- Materials include latex, agarose, glass, cellulose, sepharose, nitrocellulose, polystyrene, and other polymeric materials.
- an IgG-BP column in which the above antibody-modified peptide is bound to a column gel can be exemplified (International Publication No. 2021/080008).
- the IgG-BP column is a column in which IgG-binding peptides are immobilized. Bivalent antibodies cannot bind to the column because their binding sites are already occupied by IgG-binding peptides, and only monovalent antibodies show affinity for the column.
- the first antibody composition containing a relatively large amount of unmodified antibody and monovalent antibody is compared with the bivalent antibody by utilizing the difference in their interaction with the antibody-modified peptide.
- the second antibody composition which is relatively abundant, can be separated and purified, respectively.
- the molar ratio of unmodified antibody to monovalent antibody in the first antibody composition is 4-47:53-96, preferably 4-30:70-96, more preferably 4-20: 80-96, more preferably 4-10:90-96.
- the first antibody composition or second antibody composition thus separated and purified may be used as it is for the click reaction in the subsequent step (B), and the protein concentration of the peptide-modified antibody contained may be adjusted. It may then be used for the click reaction in step (B).
- the click reaction in step (B) is carried out between the click-reactive first atomic group of the chelating agent and the click-reactive second atomic group of the peptide-modified antibody.
- Such a click reaction forms a binding group (substituent that enables conjugation with the antibody) that connects the chelating agent and the antibody.
- step (A) can undergo a click reaction, the order of their addition does not matter.
- One of the chelating agent and the antibody may be added and then reacted, or the other may be added to a dispersion in which one of the chelating agent and the antibody is dispersed in a solvent and reacted. Alternatively, these may be simultaneously added to a reaction vessel containing a solvent and reacted.
- a solvent containing water can be used as the solvent used for the click reaction in step (B).
- Buffers such as buffered saline, Tris buffer, HEPES buffer, or tetramethylammonium acetate buffer can be used.
- the pH at 25°C is preferably 4.0 or more and 10.0 or less, more preferably 5.5 or more, from the viewpoint of achieving both the stability of the complex and the antibody and their binding efficiency. 5 or less.
- the amount of the reaction liquid is not particularly limited, but from the viewpoint of practicality in the production process, the lower limit at the start of the step (B) is preferably 0.001 mL or more, more preferably 0.01 mL or more, and 0.1 mL or more. is more preferably 1 mL or more, and the upper limit is preferably 1000 mL or less, more preferably 100 mL or less, even more preferably 10 mL or less, and even more preferably 1 mL or less, for example, preferably 0.001 mL or more and 1000 mL or less, A range of 0.1 mL or more and 10 mL or less is more preferable.
- the concentrations of the chelating agent and the antibody in the reaction solution are each independently at the start of step (B), and the lower limit thereof is preferably 0.001 ⁇ mol/L or more, more preferably 0.01 ⁇ mol/L or more, 0.1 ⁇ mol/L or more is more preferable, 1.0 ⁇ mol/L or more is still more preferable, and the upper limit is preferably 1000 ⁇ mol/L or less, more preferably 100 ⁇ mol/L or less, for example, 0.1 ⁇ mol/L or more and 1000 ⁇ mol/L.
- the following range is preferable, and a range of 1 ⁇ mol/L or more and 100 ⁇ mol/L or less is more preferable from the viewpoint of the yield of the target complex.
- the upper limit of the reaction temperature for the click reaction in step (B) is preferably 50°C or lower, more preferably 40°C or lower.
- the lower limit of the reaction temperature is not particularly limited as long as it is a temperature at which the reaction proceeds, but 15° C. or higher is preferable.
- the reaction time of the click reaction is preferably 5 minutes or more, more preferably 10 minutes or more, and preferably 24 hours or less, more preferably 20 hours or less, provided that the reaction temperature is as described above.
- the range is preferably 5 minutes or more and 24 hours or less, more preferably 10 minutes or more and 20 hours or less.
- the obtained complex may be used as it is, or may be purified using a filtration filter, a membrane filter, a column filled with various fillers, chromatography, or the like.
- the conjugates produced by steps (A) and (B) are those in which the lysine residues in the Fc region of the anti-EGFR antibody are specifically modified with a chelating agent.
- This complex comprises one or two molecules of the chelating agent per molecule of the antibody.
- the chelating agent site-specifically modifies the Fc region of the antibody of the present invention via the linker (L).
- the linker (L) includes a chelate linker (L 2 ) that connects to a chelating agent, a first atomic group that connects to the linker (L 2 ), a second atomic group that can click-react with the first atomic group, and a second atom.
- the linker (L) has a chemical structure derived from the first atomic group and the second atomic group.
- a triazole skeleton-containing structure represented by the above formula (10a) or (10b) or a pyridazine skeleton-containing structure represented by the above formula (10c) can be considered. Since Formula (10a) and Formula (10b) are in an isomer relationship, they may be contained in an arbitrary ratio.
- Radiopharmaceutical refers to a composition that contains the radioconjugate of the present invention and is in a form suitable for in vivo administration to a subject.
- Radiopharmaceuticals for example, the radioactive complex produced by the method shown in (1-6) above, as it is, or after purifying it, are produced by dissolving in a solvent mainly composed of water and isotonic with the living body can do.
- the radiopharmaceutical is preferably in the form of an aqueous solution, and may contain other pharmaceutically acceptable ingredients as necessary.
- a radiopharmaceutical is administered in an effective amount orally or parenterally such as intravenously, subcutaneously, intraperitoneally or intramuscularly to a living body, and is used for cancer treatment, cancer diagnosis, or lesion detection.
- used for The subject of administration here is humans or animals such as mice, rats, monkeys, guinea pigs, chimpanzees, sheep, goats, dogs, cats, pigs, cows or horses, but is not particularly limited. Humans are preferred.
- Preferred target diseases include cancers in which EGFR is overexpressed.
- the type of EGFR-overexpressing cancer to be treated, diagnosed or detected in the present invention is not particularly limited as long as it overexpresses EGFR.
- EGFR-overexpressing cancers may also be of any stage, either localized or metastatic, or primary or recurrent.
- overexpression means that the EGFR gene in tumor tissue is significantly amplified compared to non-tumor tissue, or the expression of EGFR protein is significantly enhanced compared to non-tumor tissue when measured by a known test method. It refers to the state in which An "effective amount” as used herein is an amount capable of obtaining a diagnostically or therapeutically effective effect in an administration subject.
- the effective amount to be administered to a subject depends on the type of subject, the weight of the subject, the dosage form (tablet, injection, etc.) and route (oral administration, parenteral administration, etc.), and the severity of the disease (e.g., cancer). Varies depending on severity. A physician or veterinarian will be able to determine an appropriate effective amount considering such factors.
- the radiopharmaceutical of the present invention When the radiopharmaceutical of the present invention is stored at room temperature, the radiopharmaceutical emits radiation at a certain rate or more at a time point that is a multiple of the half-life of 1 to 5 times the half-life of the radiometal nuclide that constitutes the radiopharmaceutical. Has chemical purity.
- the radiometal nuclide is a ⁇ -ray nuclide (e.g., Lu-177 or Y-90)
- the radiochemical purity of the complex when stored at room temperature for 7 days after completion of production is preferably 90% or more. Yes, more preferably 93% or more.
- the radiochemical purity of the complex is preferably 90% or more when stored at room temperature for 14 days after the completion of production, and more Preferably it is 94% or more.
- room temperature preferably means "ordinary temperature” as defined in the Japanese Pharmacopoeia, specifically 15 to 25°C.
- the radiochemical purity refers to the percentage of the peak radioactivity (count) corresponding to the complex with respect to the total radioactivity (count) detected when the sample is analyzed with a commercially available radiation detector. High-performance liquid chromatography and thin-layer chromatography can be used for analysis of radiochemical purity, but thin-layer chromatography is preferably used.
- the radiopharmaceutical of the present invention is preferably in the form of an aqueous solution, but is more preferably in the form of a buffer solution from the viewpoint of maintaining radiochemical purity as described above.
- the buffer any buffer used in an antibody drug containing an anti-EGFR antibody or an anti-EGFR antibody ADC as an active ingredient can be used, and non-limiting examples thereof include citrate buffer or acetate buffer. liquid can be used.
- the citrate buffer is composed of citric acid and its salts, for example, it can be composed of citric acid and its sodium salt.
- the acetate buffer is composed of acetic acid and its salts, for example, it can be composed of acetic acid and its sodium salt.
- the radiopharmaceutical of the present invention may contain any amino acid such as glycine, and may contain a solubilizing agent such as polysorbate 80.
- Radioactive metal nuclides that have a therapeutic effect specifically radionuclides that emit ⁇ rays or nuclides that emit ⁇ rays (preferably Ac-225, Y-90, Lu-177, more preferably By selecting Ac-225)
- the radiopharmaceutical of the present invention can be used for internal radiotherapy of cancer.
- the radiopharmaceutical of the present invention is administered intravenously or orally, and the radioconjugate of the present invention is accumulated in a lesion site such as a cancer primary tumor or metastatic lesion, and released from the radiometal nuclide. Radiation can destroy cancer cells at the lesion site.
- the dose and dose of the radiopharmaceutical of the present invention are determined by the efficacy of the active ingredient, the mode and route of administration, the stage of cancer progression, the body type, body weight and age of the patient, and the type and amount of the therapeutic drug used in combination for other diseases. is selected as appropriate.
- radiometal nuclide by selecting a radionuclide that emits positrons or a radionuclide that emits gamma rays (preferably Ga-68, Zr-89, In-111, more preferably Zr-89) , can be used for cancer diagnosis or lesion detection.
- Radiopharmaceuticals using positron-emitting radionuclides can be suitably used for PET (Positron Emission Tomography) examinations, and SPECT (Single Photon Emission Computed Tomography) inspection. This may be used in combination with cancer diagnosis or lesion detection in the above-described cancer radiotherapy.
- the diagnostic radiopharmaceutical for cancer of the present invention may be used for diagnosis before performing internal radiotherapy for cancer, or may be used for diagnosis after performing internal radiotherapy for cancer.
- Treatment of whether or not to perform internal radiotherapy for cancer using the radiopharmaceutical of the present invention comprising a metal nuclide that emits ⁇ -rays by being used for diagnosis before radiotherapy for cancer It can be used for selection judgment.
- it is possible to determine whether or not radiotherapy for cancer using the radiopharmaceutical of the present invention is effective, increase or decrease the dose, etc. can be used to optimize the treatment plan for
- Radiopharmaceutical (2) Another aspect of the present invention contains a chelating agent in which a radiometal nuclide is chelated and a complex of an anti-EGFR antibody as an active ingredient, does not contain a thiourea bond in the linkage between the anti-EGFR antibody and the chelating agent, When stored in a radiopharmaceutical, it has a certain percentage or more of radiochemical purity at the point in time that is a multiple of 1 to 5 half-lives based on the half-life of the radiometal nuclide that constitutes the radiopharmaceutical.
- the radiochemical purity of the complex is preferably 90% or more when stored at room temperature for 7 days after the completion of production. and more preferably 93% or more.
- the radiometal nuclide is an ⁇ -ray nuclide (e.g., Ac-225)
- the radiochemical purity of the complex is preferably 90% or more when stored at room temperature for 14 days after the completion of production, and more Preferably it is 94% or more.
- the definition of room temperature is the same as for radiopharmaceutical (1) above.
- the following methods (a) to (d) can also be used in addition to the site-specific modification method using a peptide in conjugating the chelating agent with the anti-EGFR antibody.
- the explanation is omitted.
- the peptide that site-specifically modifies the anti-EGFR antibody and the chelating agent are linked without using a thiourea bond, a radioactive complex and a radiopharmaceutical that are stable even at room temperature can be obtained.
- Site-specific modification of antibodies unlike random modification, can contain monovalent or bivalent antibodies or both in any proportion, resulting in stable quality radioconjugates and radiopharmaceuticals.
- the radioconjugate of the present invention maintains efficacy equivalent to conventional ones. Therefore, according to the present invention, it is possible to provide an anti-EGFR antibody conjugate and a radiopharmaceutical thereof with higher quality while maintaining efficacy.
- the chelating agent is DOTAGA ( ⁇ -(2-Carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid).
- the peptide has the following formula (i): (Xa)-Xaa1-(Xb)-Xaa2-(Xc)-Xaa3-(Xd) (i) (In formula (i), Xa, Xb, Xc and Xd each represent a consecutive number of X, b consecutive number of X, c consecutive number of X, and d consecutive number of X, X is an amino acid residue having neither a thiol group nor a haloacetyl group in its side chain; a, b, c and d are each independently an integer of 1 or more and 5 or less and satisfy a+b+c+d ⁇ 14, and Xaa1 and Xaa3 are each independently Represents an amino acid residue derived from an amino acid having a thiol group in the side chain, or an amino acid residue derived from an amino acid having a haloacetyl group in the side chain, provided that either one of Xaa1 and
- R 1A represents the linking site with the chelating agent
- R 2A represents the linking site with the peptide
- R 3A and R 4A One represents a hydrogen atom, a methyl group, a phenyl group or a pyridyl group, the other represents the site of connection with the chelating agent
- R5A represents the site of connection with the peptide.
- [14] contains as an active ingredient a complex of a chelating agent in which a radiometal nuclide is chelated and an anti-EGFR antibody, and does not contain a thiourea bond in the linkage between the anti-EGFR antibody and the chelating agent; A radiopharmaceutical, wherein the radiochemical purity of said complex is 90% or more when stored at room temperature for 7 days.
- the radiopharmaceutical of [14], wherein the complex is the complex of any one of [1] to [9].
- [16] The radiopharmaceutical of [15], which is used for internal radiotherapy of cancer.
- the radiopharmaceutical of [15] which is used for cancer diagnosis.
- radiopharmaceutical of [17] which is used together with the radiopharmaceutical of [16] for internal radiotherapy of cancer.
- the radiometal nuclide is 177 Lu or 90 Y, and the radiochemical purity of the complex is 90% or more when stored at room temperature for 7 days.
- the radiometal nuclide is 225 Ac, and the radiochemical purity of the complex is 90% or more when stored at room temperature for 14 days.
- Example 1 Production of conjugate with cetuximab using 225 Ac-labeled DOTAGA-DBCO (1. Antibody modification step)
- a peptide containing 17 amino acid residues represented by the following formula (P3) (SEQ ID NO: 19) was obtained by the method described in International Publication No. 2017/217347.
- the amino acid sequence of this peptide was identical to the sequence in which Xaa2 of SEQ ID NO: (2) is a lysine residue, and the side chain terminal amino group of the lysine residue was modified with the structure shown by R1 .
- cysteine residues are disulfide bonded to each other, and the N-terminus of the peptide is an atom containing an azide group, which is the second atomic group, via a linker (L 1 ) structure having diglycolic acid and eight PEGs. As a group, ethyl azide was attached.
- Gly is glycine, Pro is proline, Asp is aspartic acid, Cys is cysteine, Ala is alanine, Tyr is tyrosine, His is histidine, Lys is lysine, Glu is Glutamic acid, Leu for leucine, Val for valine, Trp for tryptophan, Thr for threonine, and Phe for phenylalanine.
- a solution containing cetuximab (manufactured by Merck) was subjected to buffer replacement using an ultrafiltration filter (Amicon Ultra-15) containing 0.02 mol/L acetic acid/sodium acetate buffer (pH 6.0). This operation was repeated twice.
- a mixture of the above peptide and buffer-substituted cetuximab in 0.02 mol/L acetic acid/sodium acetate buffer (pH 6.0) was reacted at room temperature for 30 minutes to obtain a solution containing the peptide-modified antibody. got This peptide-modified antibody is obtained by site-specifically modifying the Fc region of the antibody with the above peptide.
- DOTAGA-DBCO represented by the following formula was prepared by Bernhard et al.
- DOTAGA-Anhydride A Valuable Building Block for the Preparation of DOTA-Like Chelating Agents. Chem. Eur. J. 2012, 18, 7834-7841.
- This chelating agent was dispersed in a 0.1 mol/L sodium acetate buffer (pH 6.0) as a solvent to obtain a dispersion containing 1.7 mmol/L of the chelating agent.
- the radiochemical purity (RCP) of the obtained 225 Ac complex was measured by the following method. Specifically, a portion of the 225 Ac complex solution was developed by thin layer chromatography (manufactured by Agilent, model number: SGI0001, developing solvent: acetonitrile/water mixture (volume ratio: 1:1)), and then subjected to radio ⁇ -TLC analyzer. (MODEL GITA Star manufactured by raytest). The percentage of the peak radioactivity (counts) detected near the origin to the total radioactivity (counts) detected was defined as the RCP (%) of the 225 Ac complex. As a result, the RCP of the 225 Ac complex was 91%. The obtained 225 Ac complex solution was directly used for the labeling step.
- reaction rate (%) means the RCP of the 225 Ac complex-labeled antibody with respect to the labeling rate (%) in the complex formation step
- labeling rate (%) is the amount of radioactivity of the 225 Ac complex with respect to the amount of charged radioactivity. means the ratio (%) of
- the 225 Ac complex-labeled antibody solution obtained by reacting at 37° C. for 2 hours was purified using an ultrafiltration filter (manufactured by Merck, model number: UFC505096).
- the RCP and radiochemical yield (RCY) of the purified 225 Ac complex-labeled antibody are shown in Table 1 below.
- the methods for measuring the RCP and RCY of the 225 Ac complex-labeled antibody were as follows. That is, thin-layer chromatography (manufactured by Agilent, model number: SGI0001, developing solvent is acetonitrile: 0.1 mmol/L EDTA solution mixture (volume ratio 1:1)) was subjected to a radio ⁇ -TLC analyzer (manufactured by raytest, MODEL GITA). Star), and the percentage of the peak radioactivity (count) detected near the origin to the total radioactivity (count) detected was defined as RCP (%).
- the total radioactivity added at the start of the labeling process ( ⁇ -ray spectrometer (Ge semiconductor detector: GMX10P4-70 (manufactured by ORTEC), multichannel analyzer: M7-000 (manufactured by Seiko Easy and G), data processing : Spectrum Navigator: DS-P300 (manufactured by Seiko Easy & G Co.) and Gamma Studio: DS-P600 (manufactured by Seiko Easy & G Co.) Radioactivity amount calculated from counts measured by) Ultrafiltration for The percentage of the radioactivity recovered after purification (the amount of radioactivity calculated from counts measured with a ⁇ -ray spectrometer in the same manner as described above) was defined as RCY (%).
- Example 1 Production of Complex with Cetuximab Using 225 Ac-Labeled DOTA-DBCO The procedure of Example 1 was followed except that DOTAGA-DBCO was changed to the following DOTA-DBCO. Table 2 shows the results.
- Example 2 Preparation of a complex with cetuximab using 89Zr -labeled DOTAGA-DBCO (1. complex formation step) DOTAGA-DBCO was dispersed in 0.195 mol/L sodium acetate buffer (pH 5.5) as a solvent to prepare a dispersion containing 0.3 mmol/L of a chelating agent.
- the RCP of the obtained 89 Zr complex was measured by the following method. That is, a part of the 89 Zr complex solution was developed by thin layer chromatography (manufactured by Agilent, model number: SGI0001, developing solvent: acetonitrile/water mixture (volume ratio: 1:1)), followed by radio ⁇ -TLC analyzer. (MODEL GITA Star PS manufactured by raytest). The percentage of the peak radioactivity (counts) detected near the origin to the total radioactivity (counts) detected was defined as the RCP (%) of the 89 Zr complex. As a result, the RCP of the 89 Zr complex was 96%. The obtained 89 Zr complex solution was directly used for the labeling step.
- the amounts of 89 Zr complex and peptide-modified antibody (monovalent antibody) were 11.3 nmol and 12 nmol, respectively, and the molar ratio of DBCO to azide was about 1:1.1, respectively.
- Table 3 below shows the reaction rate (%) of the 89 Zr complex-labeled antibody of the example in the unpurified state.
- the reaction rate (%) means the RCP of the 89 Zr complex-labeled antibody with respect to the labeling rate (%) in the complex formation step
- the labeling rate (%) is the amount of radioactivity of the 89 Zr complex with respect to the amount of charged radioactivity. (%).
- the 89 Zr complex-labeled antibody solution obtained by reacting at 37° C. for 2 hours was purified using an ultrafiltration filter (manufactured by Merck, model number: UFC505096). The RCP and RCY of the purified 89Zr complex-labeled antibody are shown in Table 3 below.
- Example 2 Production of Complex with Cetuximab Using 89Zr -Labeled DOTA-DBCO The procedure of Example 2 was followed except that DOTAGA-DBCO was changed to DOTA-DBCO. Table 4 shows the results.
- Example 3 Production of complex with cetuximab using 177 Lu-labeled DOTAGA-DBCO (1. Antibody modification step) It was carried out in the same manner as described in the antibody modification step in Example 1.
- the method for producing DOTAGA-DBCO was the same as in Example 1.
- This chelating agent was dispersed in a 0.156 mol/L sodium acetate buffer (pH 5.5) as a solvent to obtain a dispersion containing 0.45 mmol/L of the chelating agent.
- 0.015 mL of this dispersion 0.015 mL of 0.156 mol/L sodium acetate buffer (pH 5.5) in which 0.225 mmol/L of gentisic acid was dissolved, and a solution containing 177 Lu ions (0.015 mL) as a radioactive metal source.
- RCP of the obtained 177 Lu complex was performed in the same manner as the RCP measurement of the radioactive complex in Example 1. As a result, the RCP of the 177 Lu complex was 100%.
- the obtained 177 Lu complex solution was directly used for the labeling step.
- Table 5 below shows the reaction rate (%) of the unpurified 177 Lu complex-labeled antibody.
- RCP and RCY of the 177 Lu complex-labeled antibody after purification using an ultrafiltration filter in the same manner as in Example 1 are shown in Table 5 below.
- Example 3 Production of complex with cetuximab using 177 Lu-labeled DOTA-DBCO The procedure of Example 3 was followed except that DOTAGA-DBCO was changed to DOTA-DBCO. Table 6 shows the results.
- Example 4 Formulation process A portion of each of the radioactive complexes produced according to the descriptions in Examples 1, 3, Comparative Example 1 and Comparative Example 3 was extracted into a 5 mL Eppendorf tube (LoBind, manufactured by Eppendorf), and buffered for storage. solution (0.1 mol/L sodium chloride and 0.1 mol/L glycine-containing 0.01 mol/L citrate buffer (pH 5.5), and 1.0 weight/volume% polysorbate 80, 0.1 mol/L sodium chloride and 0.01 mol/L citrate buffer solution (pH 5.5) containing 0.1 mol/L glycine).
- the radioconjugate produced according to the description of Comparative Example 1 containing a thiourea bond maintained an RCP of 90% or more, but less than 95%, when stored at room temperature for 7 days after completion of production. Moreover, when stored at room temperature for 14 days after completion of production, the RCP was less than 75%.
- the radioconjugate produced according to the description of Example 3 containing no thiourea bond maintained an RCP of 90% or more when stored at room temperature for 7 days after completion of production. In addition, even when stored at room temperature for 14 days after completion of production, 85% or more of RCP was maintained.
- the radioconjugate produced according to the description of Comparative Example 3 containing a thiourea bond maintained an RCP of 75% or more, but less than 90%, when stored at room temperature for 7 days after completion of production. Also, when stored at room temperature for 14 days after completion of production, the RCP was less than 65%.
- Antigen-binding activity was confirmed by in vitro autoradiography (ARG) (only the date of manufacture (0) and the last day of storage (14th day)).
- A431 cells a human epidermoid cancer cell line with high EGFR expression purchased from ECACC (European Collection of Authenticated Cell Cultures) and SNU-, a human gastric cancer cell line with low EGFR expression purchased from ATCC (American Type Culture Collection) Tumor-bearing mice were prepared by subcutaneously administering 5 ⁇ 10 6 cells and 2 ⁇ 10 6 cells of 16 cells to the flanks of female SCID Beige mice (manufactured by Charles River Japan).
- A431 and SNU-16 tumors were then excised and delivered to Tissue Tech O.C. C. T. Frozen sections were prepared by embedding in a compound (manufactured by Sakura Fine Tech Japan).
- Each of the radioconjugates obtained in Example 1 and Comparative Example 1 was added to 1% bovine serum albumin-containing PBS at 1 kBq/mL, and A431 tumor sections and SNU-16 tumor sections were immersed. After contacting the sections with the imaging plate, they were read with a scanner-type image analyzer to assess the amount of radioactivity bound to the sections. The results are shown in FIG. The specificity of each radioconjugate to EGFR can be confirmed by performing the same evaluation with a solution obtained by adding cetuximab to each solution.
- Radioconjugates produced according to the descriptions in Example 1 and Comparative Example 1 were confirmed to have binding activity to EGFR.
- Both radioconjugates prepared as described in Example 1 and Comparative Example 1 showed binding to A431 and SNU-16 tumor sections, with stronger binding to A431 tumor sections and EGFR-selective binding. Cetuximab-spiked solutions inhibited binding to A431 tumor sections, confirming the EGFR specificity of binding.
- At the end point of storage (day 14) all samples maintained selectivity of binding to EGFR. Radioactivity bound to A431 tumor sections was greater in samples using the radioconjugate prepared as described in Example 1 than in the radioconjugate prepared as described in Comparative Example 1.
- a subcutaneous tumor-bearing model of A431 cells was prepared using mice according to Evaluation 1-2, and the tumor accumulation of the radioconjugate produced according to Example 2 or Comparative Example 2 was evaluated. confirmed.
- A431 cells an EGFR-positive human epidermoid carcinoma line purchased from ATCC, were suspended in DMEM medium (gibco, manufactured by Thermo Fisher Scientific) and incubated with 5-week-old female BALB/c nu/nu (Charles River Japan).
- a tumor-bearing mouse was prepared by subcutaneously administering 5 ⁇ 10 6 cells to the flank.
- imaging was performed under the conditions shown in Table 8 using a small animal PET imaging device (PET/CT Si78, manufactured by Bruker). Representative examples of the results of PET imaging are shown in FIG. 2 (Example 2) and FIG. 3 (Comparative Example 2). Radioactivity was accumulated in tumors at a higher concentration than in other organs, and EGFR-positive tumors could be visualized.
- the radioconjugate produced according to the description of Example 2 and the radioconjugate produced according to the description of Comparative Example 2 had visually the same degree of tumor accumulation.
- a VOI volume of interest
- the radioconjugate produced according to the description of Example 2 showed 5.1% ID as a ratio of radioactivity per unit volume to the administered radioactivity.
- /cc Injected dose/cc
- Example 5 Efficacy evaluation using 225 Ac complex-labeled antibody (antitumor effect of 225 Ac complex-labeled cetuximab)
- a subcutaneous tumor-bearing model of A431 was prepared using mice, and the antitumor effect of the radioconjugates produced according to the descriptions in Example 1 and Comparative Example 1 was confirmed.
- A431 cells a human epidermoid cancer cell line highly expressing EGFR purchased from ECACC, were suspended in DMEM medium (gibco, manufactured by Thermo Fisher Scientific) and cultured in 5-week-old female BALB/c nu/nu (Japan).
- Each of the radioconjugates produced according to the descriptions in Example 1 and Comparative Example 1 was administered into the tail vein at a dose of 15 kBq/animal (100 ⁇ g/animal as cetuximab).
- a group (antibody control group) administered with cetuximab at the same amount of antibody as each radioconjugate and a vehicle group administered with storage buffer were set.
- Each group consisted of 6 animals, and the general conditions, body weight and tumor volume were measured over time until 37 days after administration.
- FIG. 4 shows changes in tumor volume over time
- FIG. 5 shows changes in body weight over time.
- Example 1 and Comparative Example 1 showed significant antitumor effects compared to the two control groups (antibody control group, vehicle group) at 37 days after administration. A difference was observed (P ⁇ 0.05 or P ⁇ 0.01). A statistical analysis software Stat Preclinica (manufactured by Takumi Information Technology Co., Ltd.) was used to test the significant difference, and Tukey's test was performed. In each group, there was no significant change in the general condition, and no signs of toxicity such as significant weight loss were observed.
- DOTAGA-DBCO (2. Complex formation step) DOTAGA-DBCO was prepared in the same manner as in Example 1. This chelating agent was dispersed in a 0.156 mol/L sodium acetate buffer (pH 6.0) as a solvent to obtain a dispersion containing 0.3 mmol/L of the chelating agent.
- the RCP of the resulting 225 Ac complex was measured in the same manner as in Example 1. As a result, the RCP of the 225 Ac complex was 95%. The obtained 225 Ac complex solution was directly used for the labeling step.
- Example 4 Production of complex with panitumumab using 225 Ac-labeled DOTA-DBCO The procedure of Example 6 was followed except that DOTAGA-DBCO was changed to DOTA-DBCO. Table 11 shows the results. The RCP and RCY of the 225 Ac complex-labeled antibody were calculated based on the amount of radioactivity obtained in the same manner as in Example 1.
- Example 7 Preparation of a complex with panitumumab using 89 Zr-labeled DOTAGA-DBCO (1. Complex formation step) A dispersion containing a chelating agent was prepared in the same manner as in Example 2, and 0.0939 mL of this dispersion and 0.0626 mL of a 0.150 mol/L gentisic acid-containing 0.156 mmol/L sodium acetate solution (pH 5.5) were added.
- 89 Zr ion-containing solution (0.1 mol/L hydrochloric acid aqueous solution, radioactivity concentration 2.6 GBq/mL, manufactured by Nihon Medi-Physics Co., Ltd., liquid volume 0.0626 mL) was mixed with 161.6 MBq as a metal source.
- the RCP of the resulting 89 Zr complex was measured in the same manner as in Example 2. As a result, the RCP of the 89 Zr complex was 98%. The obtained 89 Zr complex solution was directly used for the labeling step.
- Example 8 Formulation process 1.0 mL of each of the radioactive complexes produced according to Example 6 and Comparative Example 4 was extracted into a 5 mL Eppendorf tube (LoBind, manufactured by Eppendorf), and a formulation buffer (0.1 mol / L sodium chloride It was diluted with 1.5 mL containing 0.05 mol/L sodium acetate buffer (pH 5.8).
- the radioconjugate produced according to the description of Example 6 containing no thiourea bond maintained an RCP of 99% or more when stored at room temperature for 7 days after completion of production. Even when stored at room temperature for 14 days after completion of production, 99% or more of the RCP was maintained.
- the radioconjugate produced according to the description of Comparative Example 4 containing a thiourea bond maintained an RCP of 95% or more when stored at room temperature for 7 days after completion of production. When stored at room temperature for 14 days after completion of production, the RCP was less than 93%.
- Antigen-binding activity was evaluated by using SW48 cells, a human colon cancer-derived cell line with high EGFR expression purchased from ATCC, and human colon with low EGFR expression purchased from ATCC. Confirmed by in vitro ARG according to the description of Example 1, except that HCT-116, a cancer-derived cell line, and COLO205 cells, a human colon cancer-derived cell line with low EGFR expression purchased from ECACC, were added. (as of date of manufacture only).
- Example 9 Efficacy evaluation using 225 Ac complex-labeled antibody (cell-killing effect evaluation of 225 Ac complex-labeled panitumumab) Using cultured cells, the cell-killing effect of the radioconjugate produced as described in Example 6 was confirmed.
- COLO205 cells (RPMI 1640 medium), HCT-116 cells (Macoy's 5A medium), SW48 cells (Leibovitz's L-15 medium), human pancreatic cancer-derived cell lines with high EGFR expression purchased from ECACC MIAPaCa-2 cells (D-MEM medium) and NCI-H358 cells (RPMI 1640 medium), which is a non-small cell lung cancer-derived cell line highly expressing EGFR purchased from ATCC, were cultured in appropriate media, respectively.
- the cell-killing effect was evaluated by taking the ratio of the calculated number of viable cells to the number of viable cells under the condition where no antibody was added. The results are shown in Figures 7A-7C. Also, the obtained results were fitted by a nonlinear linear regression method using GraphPad Prism 7 (manufactured by GraphPad Software) to calculate EC50 . As a result, the EC50 for the cytocidal effect of the radioconjugate prepared as described in Example 6 was 0.5 pM for SW48 cells, 2.8 pM for NCI-H358 cells, and 2.8 pM for COLO205 cells. was 7.3 pM.
- unlabeled panitumumab has a cytocidal effect, including cells with mutations in KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) and BRAF (v-raf murine sarcoma viral oncogene homolog B1) in the evaluation cells.
- KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
- BRAF v-raf murine sarcoma viral oncogene homolog B1
- Example 10 Efficacy evaluation using 225 Ac complex-labeled antibody (apoptosis induction evaluation of 225 Ac complex-labeled panitumumab) The apoptosis induction of the radioconjugate produced as described in Example 6 on cultured cells was confirmed.
- SW48 cells and COLO205 cells which are human colon cancer-derived cells, were cultured under the same conditions as in Example 9, and radioconjugates produced according to the description of Example 6 were added at 0, 0.001, 0.01, and 0.03 , 0.1, 0.3, 1, 3 kBq/mL (0.00764, 0.0764, 0.229, 0.764, 2.29, 7.64, 22.9 ⁇ g/mL as panitumumab) added.
- Example 11 Efficacy evaluation using 225 Ac complex-labeled antibody (DNA double-strand break evaluation of 225 Ac complex-labeled panitumumab) The DNA double-strand breaking effect on cultured cells of the radioactive complex prepared as described in Example 6 was confirmed. SW48 cells, MIAPaCa-2 cells, and NCI-H358 cells were cultured in the same manner as in Example 9, and radioconjugates prepared as described in Example 6 were added at 1 kBq/mL, 10 kBq/mL, and 30 kBq/mL (3. 73, 37.3, 112 ⁇ g/mL) and cultured.
- ⁇ H2AX was stained with a DNA damage detection kit (DNA Damage Detection Kit- ⁇ H2AX-Green, manufactured by Dojindo Laboratories), and a DAPI-containing water-soluble mounting agent ( ProLong Diamond Antifade Mount with DAPI, Thermo Fisher Scientific) was used to perform nuclear staining and encapsulation. After encapsulation, ⁇ H2AX-positive sites and cell nuclei were detected using an HS all-in-one fluorescence microscope (BZ-9000, manufactured by Keyence Corporation). The results are shown in Figures 9A-9C. In each cell, the proportion of ⁇ H2AX-positive cells increased in a radioactivity-dependent manner, confirming radiation-induced DNA double-strand breaks.
- Example 12 Efficacy evaluation using 225 Ac complex-labeled antibody (antitumor effect of 225 Ac complex-labeled panitumumab) Using mice, a subcutaneous tumor-bearing model of COLO205 cells was prepared, and the antitumor effect of the radioconjugate produced as described in Example 6 was confirmed.
- COLO205 cells a human colorectal cancer-derived cell line highly expressing EGFR purchased from ECACC, were suspended in DMEM (gibco, manufactured by Thermo Fisher Scientific), and 6-week-old female BALB/c nu/nu (Japan A tumor-bearing mouse was prepared by subcutaneously administering 5 ⁇ 10 6 cells to the flanks of a mouse (manufactured by Charles River Laboratories, Inc.). After tumor-bearing treatment, the tumor volume was confirmed to be approximately 100-300 mm 3 , and individuals with a shape suitable for tumor diameter measurement were randomly grouped. The tumor volume and body weight of each mouse at that time are shown in Table 15 below.
- the radioactive complex prepared according to the description of Example 6 was administered to the tail vein at a dose of 10 kBq/animal in the high-radioactivity administration group and at a dose of 5 kBq/animal in the low-radioactivity administration group (50 ⁇ g/animal for both as panitumumab). did.
- As control groups a group administered with panitumumab at a dose of 200 ⁇ g/mouse via the tail vein (antibody control group) and a vehicle group with the storage buffer administered via the tail vein were set.
- panitumumab was intraperitoneally administered twice a week for 2 weeks at a dose of 200 ⁇ g/mouse according to the CTD (Common Technical Document) of Vectibix (registered trademark, manufactured by Takeda Pharmaceutical Company Limited).
- CTD Common Technical Document
- Vectibix registered trademark, manufactured by Takeda Pharmaceutical Company Limited
- a group antibody intraperitoneal administration group was set. Each group consisted of 6 mice, and the general conditions, body weight and tumor volume were measured over time until 33 days after administration.
- FIG. 10 shows changes in tumor volume over time.
- Example 13 Efficacy evaluation using 225 Ac complex-labeled antibody (antitumor effect of 225 Ac complex-labeled panitumumab) Using mice, a subcutaneous tumor-bearing model of HCT-116 cells was prepared, and the antitumor effect of the radioconjugate produced as described in Example 6 was confirmed. In the same manner as in Example 12, except that HCT-116 cells, a human colon cancer-derived cell line highly expressing EGFR purchased from ATCC, were suspended in DMEM (gibco, manufactured by Thermo Fisher Scientific) and used. Antitumor effect was confirmed. The tumor volume and body weight of each mouse when each solution was administered are shown in Table 16 below.
- the group setting, administered radioactivity, and administered antibody amount were the same as in Example 12. There were 6 animals in each group, and the general condition, body weight and tumor volume were measured over time until 26 days after administration. Changes in tumor volume over time are shown in FIG.
- the group to which the radioconjugate produced according to the description of Example 6 was administered with high radioactivity exhibited antitumor effects compared with the two control groups (antibody control group, vehicle group) and the antibody intraperitoneal administration group at 26 days after administration. There was a significant difference in the (P ⁇ 0.01). Tukey test was performed using statistical analysis software Stat Preclinica for determination of significant difference. A significant difference in the antitumor effect was observed between the radioconjugate-administered groups (P ⁇ 0.05), confirming the dependence of the antitumor effect on the administered radioactivity. In each group, there was no significant change in the general condition, and no signs of toxicity such as significant weight loss were observed.
- Example 14 Efficacy evaluation using 225 Ac complex-labeled antibody (antitumor effect of 225 Ac complex-labeled panitumumab) Using mice, a subcutaneous tumor-bearing model of SW48 cells was prepared, and the antitumor effect of the radioconjugate produced as described in Example 6 was confirmed. Antitumor experiments were carried out in the same manner as in Example 12, except that SW48 cells, a human colon cancer-derived cell line highly expressing EGFR purchased from ATCC, were suspended in DMEM (gibco, manufactured by Thermo Fisher Scientific) and used. We confirmed the effect. The tumor volume and body weight of each mouse when each solution was administered are shown in Table 17 below.
- the group setting, administered radioactivity, and administered antibody amount were the same as in Example 12, except that the administered antibody amount in the antibody control group was 50 ⁇ g/animal.
- FIG. 12 shows changes in tumor volume over time.
- Example 15 Efficacy comparison between 225 Ac complex-labeled panitumumab and existing drug compared to drugs.
- mice bearing tumors with COLO205 cells were prepared and the antitumor effect was confirmed.
- the tumor volume and body weight of each mouse when each solution was administered are shown in Table 18 below.
- the administration group of the radioconjugate produced according to the description of Example 6 it was administered into the tail vein at a dose of 10 kBq/animal.
- a group (oxaliplatin-administered group) was set in which 33 ⁇ L of oxaliplatin was administered to the tail vein three times at a dose of 5 mg/mL every other week.
- a vehicle group to which a radioconjugate storage buffer prepared according to the description of Example 6 was administered through the tail vein was set. There were 6 animals in each group, and the general condition was observed, and the body weight and tumor volume were measured over time until the end of the observation period. Changes in tumor volume over time are shown in FIG.
- the vertical axis of the figure represents the average tumor volume in each group, and the horizontal axis represents the number of days elapsed since administration of each drug.
- the graph represents the mean value ⁇ standard deviation of the tumor volume of each group, "*" is the time when a significant difference (p ⁇ 0.05) was observed from the oxaliplatin administration group, " ⁇ ” is from the vehicle group. indicates the time points at which a significant difference (p ⁇ 0.01) was observed.
- a culture test was performed and blood was collected.
- Example 16 Plasma stability evaluation of 225 Ac complex-labeled panitumumab Mouse plasma pool BALB/c-nu strain, Japan Charles River Laboratories), rat (plasma (pool) Wistar, Japan Charles River Laboratories), monkey (cynomolgus monkey plasma, Japan Charles River Laboratories)) plasma The stability of 225 Ac-labeled panitumumab in plasma was assessed at each time point (day 0, day 1, day 7, day 14 (human plasma only)) at 37° C. for 2 weeks. . Plasma from each animal species was incubated at 37° C. and radioconjugate prepared as described in Example 6 was added to a final concentration of 100 kBq/mL.
- the radioconjugate produced according to the description of Example 6 maintains a stability of 85% or more when stored for 7 days in the plasma of each animal species except rats. 70% or more of the stability was maintained even when stored at room temperature for 14 days.
- Example 17 Evaluation of tumor accumulation of 89 Zr complex-labeled panitumumab A subcutaneous tumor-bearing model of COLO205 cells was prepared using mice according to Example 12, and the tumor accumulation of the radioconjugate produced as described in Example 7 was performed. confirmed the gender.
- COLO205 cells a human colorectal cancer-derived cell line highly expressing EGFR purchased from ATCC, were suspended in DMEM medium and subcutaneously applied to the flanks of 5-week-old female BALB/c nu/nu (manufactured by Charles River Japan). Tumor-bearing mice were prepared by administering ⁇ 10 6 cells.
- FIG. 15 shows a representative example of the results of PET imaging. Arrows in the images indicate tumors derived from tumor-bearing COLO205 cells. In each mouse imaged, VOI was set for the tumor and muscle (thigh muscle), and SUV (Standard Uptake Value) was calculated. 0.48 ⁇ 0.02, 4.38 ⁇ 0.96 in tumor and 0.48 ⁇ 0.05 in muscle at 120 hours after administration. Using that value, the ratio of radioactivity accumulation in the muscle to the muscle was calculated. radioactivity was accumulated at a higher concentration than in other organs, and EGFR-positive tumors could be visualized.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
抗体医薬は、標的への選択性が高く比較的副作用が少ない一方で、薬効が不十分な場合がある。ペイロードの一種である化学療法剤は、強力な薬効を有するが、標的に対する選択性が低いため、がん細胞を死滅させるために必要な最小有効量が高く、一方で、毒性の観点から用量をあまり上げられないことから最大耐量が低く、治療用量域が狭いことが課題とされている。
ADCによれば、化学療法剤をがん細胞に選択的に多く届けることができるようになり、その結果、より少量で効果を示すようになり、正常細胞へ到達する化学療法剤が低減することから最大耐量も高くなることで、治療用量域が広くなることが期待される。
本発明は、ペプチドで部位特異的に修飾された抗EGFR抗体とキレート剤との複合体であって、キレート剤に放射性金属核種がキレート化しており、ペプチドとキレート剤とがリンカー(L)を介して連結しており、リンカー(L)はチオウレア結合を含まない、複合体(以下、本発明の放射性複合体とも称する)である。
本発明の放射性複合体に含まれる放射性金属核種は、α線を放出する放射性核種、β線を放出する放射性核種、ポジトロンを放出する放射性核種又はγ線を放出する放射性核種である。本発明の放射性複合体をがん治療に用いる場合は、α線を放出する放射性核種又はβ線を放出する放射性核種を用いることが好ましい。また、本発明の放射性複合体をがんの診断若しくは検出に用いる場合は、ポジトロンを放出する放射性核種又はγ線を放出する放射性核種を用いることが好ましい。α線を放出する放射性核種として、Bi-212、Bi-213、Ac-225、Th-227が例示される。また、β線を放出する放射性核種として、Cu-64、Y-90又は、Lu-177が例示される。また、ポジトロンを放出する放射性核種として、Cu-64、Ga-68、Y-86、Zr-89が例示される。また、γ線を放出する放射性核種として、Tc-99m又はIn-111が例示される。本発明の放射性複合体に含まれる放射性金属核種は、Ga-68、Zr-89、Y-90、In-111、Lu-177又はAc-225がより好ましく、Zr-89、Y-90、Lu-177又はAc-225であることが、さらに好ましい。
本発明の放射性複合体に含まれる抗体は、EGFRに特異的に結合する免疫グロブリン(以下、本発明で用いられる抗体とも称する)である。本発明で用いられる抗体は、ポリクローナル抗体であってもよいし、モノクローナル抗体であってもよいが、モノクローナル抗体が好ましい。抗体の由来は、特に限定されないが、例えば、非ヒト動物の抗体、非ヒト哺乳動物の抗体、およびヒト抗体が挙げられ、好ましくは、ヒト、ラット、マウス及びウサギの抗体を例示できる。抗体がヒト以外の種に由来する場合は、周知の技術を用いて、キメラ化又はヒト化することが好ましいが、本発明に用いられる抗体は、キメラ抗体、ヒト化抗体、またはヒト抗体であってもよい。また、本発明で用いられる抗体は、二重特異性抗体であってもよい。本発明で用いられる抗体は、例えば、IgGであり、例えば、IgG1、IgG2(例えば、IgG2aおよびIgG2b)、IgG3、またはIgG4であり得る。
セツキシマブ(Cetuximab)は、EGFRを特異的に認識するIgG1サブクラスのヒト・マウスキメラ化モノクローナル抗体であり、EGFRの活性化・二量体化を阻害することにより、結腸直腸癌、頭頸部癌、非小細胞肺癌、胃癌等に腫瘍増殖抑制効果を奏することが知られている。
セツキシマブの化学名(命名法)は、マウス抗ヒト上皮細胞増殖因子受容体モノクローナル抗体の可変部及びヒトIgG1定常部からなるヒト/マウスキメラ型モノクローナル抗体をコードするcDNAの導入によりマウスハイブリドーマSP2/0-Ag14細胞株で産生される214個のアミノ酸残基(C1025H1595N281O338S5;分子量:23,422.64)からなる軽鎖2分子と449個のアミノ酸残基(C2208H3400N582O674S15;分子量:49,363.09)からなる重鎖2分子からなる糖タンパク質である。
本明細書において、セツキシマブは、特開2005-047934号公報に記載された抗体であり、具体的には、
軽鎖アミノ酸配列(配列番号1):
セツキシマブは、RAS遺伝子野生型の治癒切除不能な進行・再発の結腸・直腸癌、頭頸部癌を適応症とする抗腫瘍剤として、臨床にて用いられており、アービタックス(Erbitux;登録商標)として入手可能である。
パニツムマブのアミノ酸配列は、ベクティビックス点滴静注100mg「タケダバイオ」についての独立行政法人医薬品医療機器総合機構による審査報告書において、以下のように示されている。
軽鎖(配列番号3):
下線が付与されたAsn(Asn)は、糖鎖結合位置であり、アスタリスクが付与されたGln(Gln*)は、一部ピログルタミン酸へ環化している。アスタリスクが2つ付与されたLys(Lys**)は、ほぼ完全に欠損している。
糖鎖構造は以下に示されている。
パニツムマブは、KRAS遺伝子野生型の治癒切除不能な進行・再発の結腸・直腸癌を適応症とする抗腫瘍剤として、臨床にて用いられており、ベクティビックス(Vectibix;登録商標)として入手可能である。
本発明においてキレート剤は、放射性金属核種が配位する部位を構造中に有するものであれば特に限定されない。キレート剤として、例えば、CB-TE2A(1,4,8,11-Tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid)、CDTA(Cyclohexane-trans-1,2-diamine tetra-acetic acid)、CDTPA(4-cyano-4-[[(dodecylthio)thioxomethyl]thio]-pentanoic acid)、DOTA(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid)、DOTMA((1R,4R,7R,10R)-α,α’,α”,α’”-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)、DOTAM(1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane)、DOTPA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra propionic acid), 1,4,7,10-tetrakis(pyridin-2-ylmethyl)-1,4,7,10-tetraazacyclododecane (Lpy), DOTA-GA(α-(2-Carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)、DOTP(((1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(methylene))tetraphosphonic acid)、DOTMP(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid))、DOTA-4AMP(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(acetamidomethylenephosphonic acid)、D02P(Tetraazacyclododecane dimethanephosphonic acid)、Deferoxamine (DFO)、DTPA(Glycine, N,N-bis[2-[bis(carboxymethyl)amino]ethyl]-)、CHX-A”-DTPA(2,2'-((2-(((1S,2R)-2-(bis(carboxymethyl)amino)cyclohexyl)(carboxymethyl)amino)ethyl)azanediyl)diacetic acid)、DTPA-BMA(5,8-Bis(carboxymethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetraazatridecan-13-oic acid)、EDTA(2,2',2”,2’”-(ethane-1,2-diylbis(azanetriyl))tetraacetic acid)、NOTA(1,4,7-Triazacyclononane-1,4,7-triacetic acid)、NOTP(1,4,7-Triazacyclononane-1,4,7-triyltris(methylenephosphonic acid))、TETPA(1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetrapropionic acid)、TETA(1,4,8,11-Tetraazacyclotetradecane-N,N',N”,N’”-tetraacetic acid)、TTHA(3,6,9,12-Tetrakis(carboxymethyl)-3,6,9,12-tetraazatetradecanedioic acid)、HEHA(1,2,7,10,13-hexaazacyclooctadecane-1,4,7,10,13,16-hexaacetic acid)、1,2-HOPO(N,N’,N”,N’”-tetra(1,2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1,5,10,14-tetraazatetradecane)、PEPA(1,4,7,10,13-pentaazacyclopentadecane-N,N’,N”,N’”,N””-pentaacetic acid)、H4octapa(N,N’-bis(6-carboxy-2-pyridylmethyl)-ethylenediamine-N,N’-diacetic acid)、H2bispa2(6,6’-({9-hydroxy-1,5-bis(methoxycarbonyl)-2,4-di(pyridine-2-yl)-3,7-diazabicyclo[3.3.1]nonane-3,7-diyl}bis(-methylene))dipicolinic acid)、H2dedpa(1,2-[{6-(carboxy)-pyridin-2-yl}-methylamino]ethane)、H2macropa(6-(1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-N,N’-methyl)picolinic acid)、H5decapa(N,N”-bis(6-carboxy-2-pyridylmethyl)-diethylenetriamine-N,N’,N”-triacetic acid)、H6phospa(N,N’-(methylenephosphonate)-N,N’-[6-(methoxycarbonyl)pyridin-2-yl]-methyl-1,2-diaminoethane)、HP-D03A(Hydroxypropyltetraazacyclododecanetriacetic acid)、porphyrinといったものが挙げられるが、下記式(A)で表される化合物が好ましい。
本発明においてペプチドは、抗体を部位特異的に、好ましくはFc領域を部位特異的に、より好ましくは抗体のFc領域におけるリシン残基を部位特異的に修飾するものであれば、特に限定されない。これにより、抗体そのものの活性(抗原認識作用、中和作用、補体活性化作用及び/又はオプソニン作用)を維持することができる。
式(i)中、Xa、Xb、Xc及びXdは、それぞれ、連続するa個のX、連続するb個のX、連続するc個のX、及び連続するd個のXを表し、
Xは、側鎖にチオール基及びハロアセチル基のいずれも有しないアミノ酸残基であり、
a、b、c及びdはそれぞれ独立に1以上5以下の整数で、かつa+b+c+d≦14を満たし
Xaa1及びXaa3は、それぞれ独立に、
側鎖にチオール基を有するアミノ酸に由来するアミノ酸残基、又は、側鎖にハロアセチル基を有するアミノ酸に由来するアミノ酸残基を表し、ただし、Xaa1及びXaa3のいずれか一方がチオール基を有するアミノ酸に由来するアミノ酸残基であり、好ましくは、Xaa1及びXaa3が連結することで、環構造が形成されており、
Xaa2は、リシン残基、アルギニン残基、システイン残基、アスパラギン酸残基、グルタミン酸残基、2-アミノスベリン酸、又はジアミノプロピオン酸、好ましくはリシン残基であり、かつXaa2が架橋剤で修飾されている。
好ましくは、本発明で用いられる抗体修飾ペプチドは、下記式(i)’で表される、13~17アミノ酸残基からなるアミノ酸配列である。
(X1-3)-C-(Xaa3’)-(Xaa4’)-H-(Xaa1’)-G-(Xaa2’)-L-V-W-C-(X1-3) (i)’
Cはシステイン残基であり、
Hはヒスチジン残基であり、
Xaa1’はリシン残基、システイン残基、アスパラギン酸残基、グルタミン酸残基、2-アミノスベリン酸、又はジアミノプロピオン酸であり、
Gはグリシン残基であり、
Xaa2’はグルタミン酸残基又はアスパラギン残基であり、
Lはロイシン残基であり、
Vはバリン残基であり、
Wはトリプトファン残基であり、
Xaa3’はアラニン残基、セリン残基又はトレオニン残基であり、かつ
Xaa4’はチロシン残基又はトリプトファン残基である。
上記式(i)’で、N末端又はC末端のX1-3という表記は、システイン(C又はCys)以外の独立的に任意のアミノ酸残基Xが1~3個連続していることを意味し、それを構成するアミノ酸残基は同じか又は異なる残基であるが、好ましくは3個すべてが同じ残基でない配列からなる。
(2)GPDCAYH(Xaa2)GELVWCTFH(配列番号6)
(3)RCAYH(Xaa2)GELVWCS(配列番号7)
(4)GPRCAYH(Xaa2)GELVWCSFH(配列番号8)
(5)SPDCAYH(Xaa2)GELVWCTFH(配列番号9)
(6)GDDCAYH(Xaa2)GELVWCTFH(配列番号10)
(7)GPSCAYH(Xaa2)GELVWCTFH(配列番号11)
(8)GPDCAYH(Xaa2)GELVWCSFH(配列番号12)
(9)GPDCAYH(Xaa2)GELVWCTHH(配列番号13)
(10)GPDCAYH(Xaa2)GELVWCTFY(配列番号14)
(11)SPDCAYH(Xaa2)GELVWCTFY(配列番号15)
(12)SDDCAYH(Xaa2)GELVWCTFY(配列番号16)
(13)RGNCAYH(Xaa2)GQLVWCTYH(配列番号17)
(14)G(Xaa1)DCAYH(Xaa2)GELVWCT(Xaa3)H(配列番号18)
リンカー(L)は、本発明の放射性複合体において、キレート剤とペプチドとを連結できるものであれば特に限定されない。本発明で用いられるリンカー(L)は、チオウレア結合を含むものでなければ特に限定されず、置換又は無置換のアルキル基、置換又は無置換のヘテロアルキル基、ポリエチレングリコール(PEG)基、ペプチド、糖鎖、ジスルフィド基、アミド基、及びこれらの組み合わせなどが挙げられる。
本明細書においてリンカー(L)とは、ペプチドで修飾された抗EGFR抗体とキレート剤との接続に用いられるリンカーの総称であり、抗体修飾リンカー(L1)及びキレートリンカー(L2)を含む用語である。抗体修飾リンカー(L1)は、詳細は後述するが、(1-4)で説明したペプチドのN末端側に導入されるものであり、キレートリンカー(L2)も、詳細は後述するが、(1-3)で説明したキレート剤の官能基に導入されるものである。
本発明の放射性複合体の製造方法は、キレート剤と抗EGFR抗体とをコンジュゲーションするコンジュゲーション工程と、放射性金属核種とキレート剤との錯体を形成する錯体形成工程との2つの工程から製造することができる。コンジュゲーション工程は、錯体形成工程の前であってもよいし錯体形成工程の後であってもよい。
錯体形成後、ろ過フィルター、メンブランフィルター、種々の充填剤を充填したカラム、クロマトグラフィー等を用いて、得られた錯体を精製してもよい。
より好ましい態様において、錯体形成工程(A)では、放射性金属核種と、クリック反応可能な第1原子団を抗体と複合化を可能とするための置換基として有するキレート剤と、の間で錯体を形成する。次いで、コンジュゲーション工程(B)では、前述した式(i)で示す抗体修飾ペプチドとクリック反応可能な第2原子団とを有する抗体修飾リンカー(L1)を用いて、Fc領域を部位特異的に修飾されたペプチド修飾抗体と、工程(A)で得られた錯体形成されたキレート剤との間でクリック反応を実行し、本発明の放射性複合体を得る。
以下、工程(A)及び(B)について、詳述する。
A-B-C ・・・(ii)
式(ii)中、Aは、前述したキレート剤であり、BとCとの総称がキレートリンカー(L2)である
*-((Li)m-Z)k-Lii-AG2 ・・・(S1)
(式中、*は、ペプチドのN末端又はC末端との結合部位を示し、
Liは、ポリエチレングリコール(PEG)リンカー部であり、
mは、1以上50以下の整数であり、
Zは、(Li)mとLiiとを結合する第2リンカー部であり、
kは、0又は1であり、
Liiは、第2のPEGリンカー部であり、
AG2は第2原子団である。)
該混合工程における抗体修飾ペプチドと抗EGFR抗体の混合比率は、特に限定しない。抗体修飾ペプチドと抗EGFR抗体のモル比率は、例えば1:1~20:1、好ましくは2:1~20:1又は5:1~10:1とすることができる。
未修飾抗体と、一価抗体と、二価抗体とを分離精製する場合は、上記のいずれの精製方法で分離精製してもよいが、種々の充填剤を充填したカラムを用いることができ、例えば、プロテインA、プロテインG又は上述の抗体修飾ペプチド等のタンパク質が担体に結合した充填剤が充填されたカラムを用いることができる。このようなカラムに充填される充填剤の担体の形状としては、ゲル(例えばカラム用ゲル)、粒子、ビーズ、ナノ粒子、微粒子及びマクロビーズなどの形状が挙げられ、担体の材質としては、磁性物質、ラテックス、アガロース、ガラス、セルロース、セファロース、ニトロセルロース、ポリスチレン、その他の高分子材料が挙げられる。具体的には上述の抗体修飾ペプチドを、カラム用ゲルに結合させたIgG-BPカラムが例示できる(国際公開第2021/080008号)。
放射性医薬とは、本発明の放射性複合体を含み、対象の生体内への投与に適した形態となっている組成物を指す。放射性医薬は、例えば上述の(1-6)に示す方法で製造した放射性複合体をそのままで、又はこれを精製したあとで、水を主体とし、且つ生体と等張の溶媒に溶解させて製造することができる。この場合、放射性医薬は水溶液の形態であることが好ましく、必要に応じて、薬学的に許容される他の成分を含んでいてもよい。放射性医薬は、その有効量が、経口的に、又は静脈内、皮下、腹腔内若しくは筋肉内等の非経口的に生体に投与され、がんの治療、がんの診断、あるいは病巣の検出等に用いられる。
ここで投与対象としてはヒト、またはマウス、ラット、サル、モルモット、チンパンジー、ヒツジ、ヤギ、イヌ、ネコ、ブタ、ウシもしくはウマなどの動物であるが、特に限定されるものではない。好ましくはヒトである。
好ましい対象疾患としてEGFRが過剰発現しているがんが挙げられる。本発明で治療、診断若しくは検出されるEGFRが過剰発現しているがんは、EGFRを過剰発現していればその種類は特に限定されないが、例えば、結腸・直腸癌(特に、RAS遺伝子野生型の治癒切除不能な進行・再発性の癌)、頭頸部癌を挙げることができる。また、EGFRが過剰発現しているがんは、いかなる病期のがんであってもよく、限局性若しくは転移性、又は原発性若しくは再発性のいずれであってもよい。ここで「過剰発現」とは、公知の検査手法で測定した場合に腫瘍組織におけるEGFR遺伝子が非腫瘍組織に比べて有意な増幅又はEGFRタンパク質の発現が非腫瘍組織に比べて有意な亢進が観察される状態をいう。
ここでの「有効量」とは、投与対象における診断上または治療上有効な効果を得ることができる量である。対象に投与するべき有効量は、対象の種類、対象の体重、投与する剤形(錠剤、注射剤など)および経路(経口投与、非経口投与など)、および疾患(例、がん)の重篤度などにより異なる。医師や獣医師はそれらの因子を考慮して、適切な有効量を決定することができる。
ここで、放射化学的純度は、試料を市販の放射線検出器で分析した場合に検出された全放射能(カウント)に対する、複合体に相当するピークの放射能(カウント)の百分率をいう。放射化学的純度の分析には高速液体クロマトグラフィーや薄層クロマトグラフィーを用いることができるが、薄層クロマトグラフィーを用いることが好ましい。より好ましくは後述する実施例に記載の条件を用いた薄層クロマトグラフィーを用いる。
前述のとおり、本発明の放射性医薬は、水溶液の形態であることが好ましいが、上記の通り放射化学的純度を維持する観点から緩衝液の形態がより好ましい。緩衝液としては、抗EGFR抗体または抗EGFR抗体のADCを有効成分として含有する抗体医薬で使用されている任意の緩衝液を用いることができ、特に限定されない一例として、クエン酸緩衝液または酢酸緩衝液を使用することができる。クエン酸緩衝液は、クエン酸とその塩から構成され、例えば、クエン酸とそのナトリウム塩から構成することができる。酢酸緩衝液は、酢酸とその塩から構成され、例えば、酢酸とそのナトリウム塩から構成することができる。本発明の放射性医薬には、グリシンなどの任意のアミノ酸を含んでいてもよいし、ポリソルベート80などの可溶化剤を含んでいてもよい。
本発明の他の態様は、放射性金属核種がキレート化したキレート剤と、抗EGFR抗体との複合体を有効成分として含有し、抗EGFR抗体とキレート剤との連結にチオウレア結合を含まず、室温で保管したとき、その放射性医薬を構成する放射性金属核種の半減期を基準として、半減期の1以上5以下の倍数の期間経過時点において、一定の割合以上の放射化学的純度を有する。上記の放射性金属核種がβ線核種(例えば、Lu-177又はY-90)であるとき、好ましくは、室温で製造終了から7日間保管した時の前記複合体の放射化学的純度が90%以上であり、より好ましくは93%以上である。また、放射性金属核種がα線核種(例えば、Ac-225)であるときに、好ましくは、室温で製造終了から14日間保管した時の複合体の放射化学的純度が90%以上であり、より好ましくは94%以上である。室温の定義は上述の放射性医薬(1)と同様である。
放射性医薬(2)では、キレート剤と、抗EGFR抗体との複合化において、ペプチドを用いた部位特異的修飾の方法に加えて、以下(a)から(d)の方法も使用することができるが、これ以外は、放射性医薬(1)と同様であるため、説明を省略する。
(a)抗体のヒンジ部位にあるポリペプチド鎖間のジスルフィド結合(SS結合)を部分的に還元することによって生じるスルフヒドリル(SH)基に対して、SH基に反応性を有するマレイミド基を持つキレート剤またはリンカー(L)で修飾する方法
(b)遺伝子工学によるアミノ酸変異によって、抗体に新たに導入されたシステインに対してマレイミド基をもつキレート剤またはリンカー(L)を修飾する方法
(c)遺伝子工学によるアミノ酸変異によって、抗体に新たに導入されたアジド化リシンのアジド基に、クリック反応を利用して、アルキン(例えばDibenzocyclooctyne: DBCO)をもつキレート剤またはリンカー(L)を修飾する方法
(d)トランスグルタミナーゼを利用して、抗体の特定の位置に導入されたグルタミンに、リシンの側鎖を有するキレート剤またはリンカー(L)を修飾する方法
[1]ペプチドで部位特異的に修飾された抗EGFR抗体とキレート剤との複合体であって、
前記キレート剤に放射性金属核種がキレート化しており、
前記ペプチドとキレート剤とがリンカー(L)を介して連結しており、前記リンカー(L)はチオウレア結合を含まない、複合体。
[2]前記キレート剤がDOTAGA(α-(2-Carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)である、[1]に記載の複合体。
[3]前記ペプチドが、下記の式(i):
(Xa)-Xaa1-(Xb)-Xaa2-(Xc)-Xaa3-(Xd)・・・(i)
(式(i)中、Xa、Xb、Xc及びXdは、それぞれ、連続するa個のX、連続するb個のX、連続するc個のX、及び連続するd個のXを表し、
Xは、側鎖にチオール基及びハロアセチル基のいずれも有しないアミノ酸残基であり、
a、b、c及びdはそれぞれ独立に1以上5以下の整数で、かつa+b+c+d≦14を満たし
Xaa1及びXaa3は、それぞれ独立に、
側鎖にチオール基を有するアミノ酸に由来するアミノ酸残基、又は、側鎖にハロアセチル基を有するアミノ酸に由来するアミノ酸残基を表し、ただし、Xaa1及びXaa3のいずれか一方がチオール基を有するアミノ酸に由来するアミノ酸残基であり、
Xaa1及びXaa3が連結することで、環構造が形成されており、
Xaa2は、リシン残基、アルギニン残基、システイン残基、アスパラギン酸残基、グルタミン酸残基、2-アミノスベリン酸、又はジアミノプロピオン酸であり、かつXaa2が架橋剤で修飾されている。)で表される、13~17アミノ酸残基からなるアミノ酸配列である、[1]又は[2]に記載の複合体。
[4]前記放射性金属核種がAc-225、Y-90、Lu-177又はZr-89である、[1]乃至[3]いずれか一項に記載の複合体。
[5]前記リンカー(L)が式(10a)、式(10b)又は式(10c)を含む、[1]乃至[4]いずれか一項に記載の複合体。
[6]前記ペプチドとの連結部位と前記ペプチドとの間に、ポリエチレングリコール基を含む、[5]に記載の複合体。
[7]N末端にアジド基が導入された前記ペプチドが部位特異的に修飾している抗EGFR抗体と、下記式で表されるDOTAGA-DBCOの放射性金属錯体とをクリック反応させることで複合化した、[1]乃至[6]いずれか一項に記載の複合体。
[9]前記抗EGFR抗体がパニツムマブである、[1]乃至[7]いずれか一項に記載の複合体。
[10][1]乃至[9]いずれか一項に記載の複合体を有効成分として含有する放射性医薬。
[11]がんの放射線内用療法に用いられる、[10]に記載の放射性医薬。
[12]がんの診断に用いられる、[10]に記載の放射性医薬。
[13][11]に記載された放射性医薬を用いたがんの放射線内用療法に併用される、[12]に記載の放射性医薬。
[14]放射性金属核種がキレート化したキレート剤と、抗EGFR抗体との複合体を有効成分として含有し
抗EGFR抗体とキレート剤との連結にチオウレア結合を含まず、
室温で7日間保管した時の前記複合体の放射化学的純度が90%以上である、放射性医薬。
[15]前記複合体が[1]乃至[9]いずれか一項に記載の複合体である、[14]に記載の放射性医薬。
[16]がんの放射線内用療法に用いられる、[15]に記載の放射性医薬。
[17]がんの診断に用いられる、[15]に記載の放射性医薬。
[18][16]に記載された放射性医薬を用いたがんの放射線内用療法に併用される、[17]に記載の放射性医薬。
[19]放射性金属核種がキレート化したキレート剤と、抗EGFR抗体との複合体を有効成分として含有し
抗EGFR抗体とキレート剤との連結にチオウレア結合を含まない、下記(1)または(2)の条件を満たす放射性医薬:
(1)前記放射性金属核種が177Lu又は90Yであって、室温で7日間保管した時の前記複合体の放射化学的純度が90%以上である。
(2)前記放射性金属核種が225Acであって、室温で14日間保管した時の前記複合体の放射化学的純度が90%以上である。
[20]放射性金属核種がキレート化したキレート剤と、抗EGFR抗体との複合体を有効成分として含有し
抗EGFR抗体とキレート剤との連結にチオウレア結合を含まず、
前記放射性金属核種の半減期を基準として、前記半減期の1以上5以下の倍数の期間経過時点において、前記複合体の放射化学的純度が90%以上である放射性医薬。
(1.抗体修飾工程)
国際公開第2017/217347号に記載の方法で、下記式(P3)(配列番号19)で表される17個のアミノ酸残基を含むペプチドを得た。このペプチドのアミノ酸配列は、配列番号(2)のXaa2がリシン残基である配列と同一であり、リシン残基の側鎖末端アミノ基がR1で示される構造で修飾されていた。また、2つのシステイン残基で互いにジスルフィド結合しており、ペプチドのN末端はジグリコール酸及び8つのPEGを有するリンカー(L1)構造を介して、第2原子団であるアジド基を含む原子団として、エチルアジドが結合しているものであった。
上述のペプチドと、緩衝液置換したセツキシマブとを、0.02mol/L酢酸・酢酸ナトリウム緩衝液(pH6.0)に混合した混合液を、室温で30分間反応させて、ペプチド修飾抗体を含む溶液を得た。このペプチド修飾抗体は、上記のペプチドによって抗体のFc領域が部位特異的に修飾されたものである。
下記式で表されるDOTAGA-DBCOをBernhard et al. DOTAGA-Anhydride: A Valuable Building Block for the Preparation of DOTA-Like Chelating Agents.Chem.Eur. J.2012,18, 7834-7841に記載の方法を基にして製造した。このキレート剤を、溶媒として0.1mol/L酢酸ナトリウム緩衝液(pH6.0)に分散させて、キレート剤を1.7mmol/L含む分散液とした。この分散液0.01mLと、0.1mol/L酢酸ナトリウム緩衝液(pH6.0)0.15mLと、放射性金属源として225Acイオン含有溶液(0.2mol/L塩酸水溶液、放射能濃度358MBq/mL、Oak Ridge National Laboratory製より調製、液量0.01mL)約3.6MBq(検定日時放射能量から減衰計算した計算値)とを混合した反応液を、加熱条件下で反応させて、225Ac錯体溶液を得た。キレート剤と放射性金属イオンとのモル比率は、キレート剤:225Acイオン=約2290:1であり、反応液の加熱温度は70℃、加熱時間は30分間とした。
上述の工程(2)を経て得られた未精製のままの225Ac錯体の溶液に、上記の工程(1)で得られたペプチド修飾抗体(一価抗体)を含む溶液を添加し、37℃で120分間クリック反応させて、225Ac錯体標識抗体を得た。225Ac錯体の量及びペプチド修飾抗体(一価抗体)の量はそれぞれ17nmol及び20nmolであり、DBCO基とアジド基とのモル比はそれぞれ約1:1.2であった。未精製時の225Ac錯体標識抗体の反応率(%)を以下の表1に示す。ここで、反応率(%)とは、錯体形成工程での標識率(%)に対する225Ac錯体標識抗体のRCPを意味し、標識率(%)とは仕込み放射能量に対する225Ac錯体の放射能量の割合(%)を意味する。
更に、37℃で2時間反応させて得られた225Ac錯体標識抗体の溶液を限外ろ過フィルター(Merck社製、型番:UFC505096)を用いて精製した。精製後の225Ac錯体標識抗体のRCP及び放射化学的収率(RCY)を以下の表1に示す。
DOTAGA-DBCOを下記DOTA-DBCOに変えた以外は、実施例1に準じて操作を行った。結果を表2に示した。
(1.錯体形成工程)
DOTAGA-DBCOを、溶媒として0.195mol/L酢酸ナトリウム緩衝液(pH5.5)に分散させて、キレート剤を0.3mmol/L含む分散液とした。この分散液0.0375mLと、放射性金属源として89Zrイオン含有溶液(0.1mol/L塩酸水溶液、放射能濃度5.2GBq/mL、日本メジフィジックス株式会社製より調製、液量0.0375mL)195MBqとを混合した反応液を、加熱条件下で反応させて、89Zr錯体溶液を得た。キレート剤と放射性金属イオンとのモル比率は、キレート剤:89Zrイオン=約85:1であり、反応液の加熱温度は70℃、加熱時間は60分間とした。
上述の工程(1)を経て得られた未精製のままの89Zr錯体の溶液と、実施例1と同様にして得られたペプチド修飾抗体(一価抗体)を含む溶液とを、未精製のままそれぞれ0.1mol/L塩化ナトリウム及び0.1mol/Lグリシン含有0.01mol/Lクエン酸緩衝液(pH5.5)に添加し、37℃で90分間クリック反応させて、実施例2の89Zr錯体標識抗体を得た。89Zr錯体の量及びペプチド修飾抗体(一価抗体)の量はそれぞれ11.3nmol及び12nmolであり、DBCOとアジドとのモル比はそれぞれ約1:1.1であった。未精製時の実施例の89Zr錯体標識抗体の反応率(%)を以下の表3に示す。ここで、反応率(%)とは、錯体形成工程での標識率(%)に対する89Zr錯体標識抗体のRCPを意味し、標識率(%)とは仕込み放射能量に対する89Zr錯体の放射能量(%)を意味する。
更に、37℃で2時間反応させて得られた89Zr錯体標識抗体の溶液を限外ろ過フィルター(Merck社製、型番:UFC505096)を用いて精製した。精製後の89Zr錯体標識抗体のRCP及びRCYを以下の表3に示す。
DOTAGA-DBCOをDOTA-DBCOに変えた以外は、実施例2に準じて操作を行った。結果を表4に示した。
(1.抗体修飾工程)
実施例1での抗体修飾工程に記載の方法と同様に行った。
DOTAGA-DBCOの製造方法は実施例1と同様に行った。このキレート剤を、溶媒として0.156mol/L酢酸ナトリウム緩衝液(pH5.5)に分散させて、キレート剤を0.45mmol/L含む分散液とした。この分散液0.015mLと、0.225mmol/Lのゲンチジン酸を溶解した0.156mol/L酢酸ナトリウム緩衝液(pH5.5)0.015mLと、放射性金属源として177Luイオン含有溶液(0.04mol/L塩酸水溶液、放射能濃度3.4GBq/mL,POLATOM製より調製、液量0.0375mL)127MBqとを混合した反応液を、加熱条件下で反応させて、177Lu錯体溶液を得た。キレート剤と放射性金属イオンとのモル比率は、キレート剤:177Luイオン=約38:1であり、反応液の加熱温度は70℃、加熱時間は5分間とした。
上述の工程(2)を経て得られた未精製のままの177Lu錯体の溶液と、上記の工程(1)で得られたペプチド修飾抗体(一価抗体)を含む溶液とを、それぞれ0.1mol/L塩化ナトリウム及び0.1mol/Lグリシン含有0.01mol/Lクエン酸緩衝液(pH5.5)に添加し、37℃で120分間クリック反応させて、177Lu錯体標識抗体を得た。177Lu錯体の量及びペプチド修飾抗体(一価抗体)の量はそれぞれ6.75nmol及び7.5nmolであり、DBCO基とアジド基とのモル比はそれぞれ約1:1.1であった。未精製時の177Lu錯体標識抗体の反応率(%)を以下の表5に示す。
また、実施例1と同様に限外ろ過フィルターを用いて精製した後の177Lu錯体標識抗体のRCP及びRCYを以下の表5に示す。
DOTAGA-DBCOをDOTA-DBCOに変えた以外は、実施例3に準じて操作を行った。結果を表6に示した。
実施例1、実施例3、比較例1及び比較例3の記載に従って製造する放射性複合体をそれぞれ5mLエッペンチューブ(LoBind、エッペンドルフ社製)に一部抜き取り、保存緩衝液(0.1mol/L塩化ナトリウム及び0.1mol/Lグリシン含有0.01mol/Lクエン酸緩衝液(pH5.5)、並びに1.0重量/体積%ポリソルベート80、0.1mol/L塩化ナトリウム及び0.1mol/Lグリシン含有0.01mol/Lクエン酸緩衝液(pH5.5)混液)で希釈した。
実施例4で得られた各放射性複合体を、室温で2週間保存し、各時間点(0日点、1日点、7日点、及び/又は14日点)において、RCP及び抗原結合活性を評価した。なお、製造終了から7日間は、放射性金属核種がLu-177である場合には、約1半減期に相当し、製造終了から14日間は、放射性金属核種がAc-225である場合には、約1.5半減期に相当し、放射性金属核種がLu-177である場合には約2半減期に相当する。
[評価1-1]RCP(放射化学的純度)
RCPを薄層クロマトグラフィー(TLC)で分析した。TLCの条件は、実施例1で反応率を調べるときに使用した条件と同様とした。
結果を表7に示す。
チオウレア結合を含む比較例1の記載に従って製造した放射性複合体は、製造終了後室温で7日間保存した場合、RCPとして90%以上が維持されていたが、95%を下回っていた。また、製造終了後室温で14日間保存した場合、RCPとして75%を下回っていた。
チオウレア結合を含まない実施例3の記載に従って製造した放射性複合体は、製造終了後室温で7日間保存した場合、RCPとして90%以上が維持されていた。また、製造終了後室温で14日間保存した場合でもRCPとして85%以上が維持されていた。
チオウレア結合を含む比較例3の記載に従って製造した放射性複合体は、製造終了後室温で7日間保存した場合、RCPとして75%以上が維持されていたが、90%を下回っていた。また、製造終了後室温で14日間保存した場合、RCPとして65%を下回っていた。
抗原結合活性はin vitro オートラジオグラフィー(ARG)で確認した(製造日(0)及び保存最終日(14日点)のみ)。ECACC(European Collection of Authenticated Cell Cultures)から購入したEGFR高発現のヒト類上皮がん細胞株であるA431細胞およびATCC(American Type Culture Collection)から購入したEGFR低発現のヒト胃がん細胞株であるSNU-16細胞を雌性SCID Beigeマウス(日本チャールス・リバー社製)の脇腹皮下にそれぞれ5×106cellsおよび2×106cells投与して担癌マウスを作製した。その後、A431腫瘍およびSNU-16腫瘍を摘出してティシュー・テック O.C.T.コンパウンド(サクラファインテックジャパン社製)に包埋して凍結切片を作製した。1%ウシ血清アルブミン含有PBSに実施例1および比較例1で得られた放射性複合体をそれぞれ1kBq/mLとなるように添加し、A431腫瘍切片およびSNU-16腫瘍切片を浸漬した。切片をイメージングプレートにコンタクトした後、スキャナータイプ画像解析装置で読み取り、切片に結合した放射能量を評価した。結果を図1に示す。
それぞれの溶液にセツキシマブを添加した溶液で同様に評価を行うことで、各放射性複合体のEGFRに対する特異性を確認することができる。
保存最終点(14日点)において、実施例1および比較例1の記載に従って製造した放射性複合体のいずれでもEGFRに対する結合活性が確認された。実施例1および比較例1の記載に従って製造した放射性複合体はどちらもA431腫瘍切片及びSNU-16腫瘍切片に結合を示し、A431腫瘍切片により強く結合し、EGFR選択的な結合を示した。セツキシマブを添加した溶液ではA431腫瘍切片に対する結合が阻害され、結合のEGFR特異性が確認される。保存最終点(14日点)において、すべてのサンプルでEGFRに対する結合の選択性が維持されていた。A431腫瘍切片に結合した放射能は実施例1の記載に従って製造した放射性複合体を用いたサンプルの方が比較例1の記載に従って製造した放射性複合体よりも多くなった。
評価1-2に準じてマウスを用いてA431細胞の皮下担癌モデルを作製し、実施例2又は比較例2の記載に従って製造した放射性複合体の腫瘍集積を確認した。
ATCCから購入したEGFR陽性のヒト類上皮癌株であるA431細胞をDMEM培地(gibco、サーモフィッシャーサイエンティフィック社製)に懸濁し、5週齢の雌性BALB/c nu/nu(日本チャールス・リバー社製)の脇腹皮下に5×106cells投与して担癌マウスを作製した。腫瘍体積がおおよそ100~250mm3となるまで成長させ、実施例2又は比較例2の記載に従って製造した放射性複合体を3.7MBq/匹(各n=3)の用量で尾静脈内投与した。投与後96時間後に小動物PETイメージング装置(PET/CT Si78、Bruker社製)を用いて表8の条件で撮像を行った。
PET撮像を実施した結果の代表例を図2(実施例2)及び図3(比較例2)に示す。腫瘍には他の臓器と比較して放射能が高い濃度で集積し、EGFR陽性腫瘍の描出が可能であった。また、実施例2の記載に従って製造した放射性複合体と、比較例2の記載に従って製造した放射性複合体とでは、腫瘍集積性は視覚的に同程度であり、図2又は図3に示した代表例の画像において腫瘍にVOI(関心体積)を設定して解析した場合、実施例2の記載に従って製造した放射性複合体が、投与放射能に対する単位体積あたりの放射能の割合として5.1%ID/cc(Injected dose/cc)であり、比較例2の記載に従って製造した放射性複合体が4.6%ID/ccで同程度であった。
マウスを用いてA431の皮下担癌モデルを作製し、実施例1及び比較例1の記載に従って製造した放射性複合体の抗腫瘍効果を確認した。
ECACCから購入したEGFR高発現のヒト類上皮がん細胞株であるA431細胞をDMEM培地(gibco、サーモフィッシャーサイエンティフィック社製)に懸濁し、5週齢の雌性BALB/c nu/nu(日本チャールス・リバー社製)の脇腹皮下に5×106cells投与して担癌マウスを作製した。腫瘍体積が200~350mm3となるまで成長させ、腫瘍径測定に適した形状の個体から無作為に群分けを実施した。その際の各マウスの腫瘍体積と体重を表9に示す。腫瘍体積は以下の式に従って算出した。
腫瘍体積(mm3)=(腫瘍長径×(腫瘍短径)2)×1/2
(1.抗体修飾工程)
国際公開第2017/217347号に記載の方法で、上記(P3)で表される17個のアミノ酸残基を含むペプチドを得た。
DOTAGA-DBCOを実施例1と同様にして製造した。このキレート剤を、溶媒として0.156mol/L酢酸ナトリウム緩衝液(pH6.0)に分散させて、キレート剤を0.3mmol/L含む分散液とした。この分散液0.0136mLと0.156mol/L酢酸ナトリウム緩衝液(pH5.5)0.0136mLと、放射性金属源として225Acイオン含有溶液(0.1mol/L塩酸水溶液、放射能濃度210~222MBq/mL、Oak Ridge National Laboratory製より調製、液量0.0093mL)1.95~2.06MBq(検定日時放射能から減衰計算した計算値)とを混合した反応液を加熱条件下で反応させて、225Ac錯体溶液を得た。その際のキレート剤と放射性金属イオンとのモル比率は、キレート剤:225Acイオン=約989:1であり、反応液の加熱条件は70℃、加熱時間は30分とした。
上述の工程(2)を経て得られた未精製のままの225Ac錯体の溶液に、上記の工程(1)で得られるペプチド修飾抗体(一価抗体)を含む溶液を添加し、37℃で2時間クリック反応させて、225Ac錯体標識抗体を得た。DBCO基とアジド基とのモル比はそれぞれ約1:1.2であった。未精製時の225Ac錯体標識抗体の反応率を以下の表10に示す。
更に、37℃で2時間反応させて得られた225Ac錯体標識抗体の溶液を限外ろ過フィルター(Merck社製、型番:UFC803096)を用いて精製した。精製後の225Ac錯体標識抗体のRCP及びRCYを以下の表10に示す。なお、225Ac錯体標識抗体のRCP及びRCYは実施例1と同様の方法で得られた放射能量を基に算出した。
DOTAGA-DBCOをDOTA-DBCOに変更した以外は、実施例6に準じて操作を行った。結果を表11に示す。なお、225Ac錯体標識抗体のRCP及びRCYは実施例1と同様の方法で得られた放射能量を基に算出した。
(1.錯体形成工程)
実施例2と同様に、キレート剤を含む分散液を調整し、この分散液0.0939mLと0.150mol/Lゲンチジン酸含有0.156mmol/L酢酸ナトリウム溶液(pH5.5)0.0626mL、放射性金属源として89Zrイオン含有溶液(0.1mol/L塩酸水溶液、放射能濃度2.6GBq/mL、日本メジフィジックス株式会社製より調製、液量0.0626mL)161.6MBqとを混合し、実施例2に準じて、89Zr錯体溶液を得た。その際のキレート剤と放射性金属イオンとのモル比率は、キレート剤:89Zrイオン=約236:1であった。
上述の工程(1)を経て得られた未精製のままの89Zr錯体溶液と実施例6と同様にして得られたペプチド修飾抗体(一価抗体)を含む溶液とを混合し、37℃で90分間クリック反応させて、89Zr錯体標識抗体を得た。DBCOとアジドとのモル比はそれぞれ約1:1であった。未精製時の89Zr錯体標識抗体の反応率(%)を以下の表12に示す。
さらに、37℃で2時間反応させて得られた89Zr錯体標識抗体の溶液を限外ろ過フィルターを用いて精製した。精製後の89Zr錯体標識抗体のRCP及びRCY(%)を以下の表12に示す。なお、89Zr錯体標識抗体のRCP及びRCYは実施例1と同様の方法で得られた放射能量を基に算出した。
実施例6及び比較例4に従って製造した放射性複合体をそれぞれ5mLエッペンチューブ(LoBind、エッペンドルフ社製)に1.0mL抜き取り、処方緩衝液(0.1mol/L塩化ナトリウム含有0.05mol/L酢酸ナトリウム緩衝液(pH5.8))1.5mLで希釈した。
実施例8で得られた各放射性複合体を、室温(24.5~25.5℃)で2週間保存し、各時間点(0日点、1日点、7日点、及び14日点)において、RCP、凝集体の割合及び抗原結合活性を評価した。
[評価3-1]RCP
RCPはTLC分析結果から算出した。TLCの条件は実施例1において反応率を評価した際に使用した条件と同様とした。結果を表13に示す。
凝集体の割合は、サイズ排除クロマトグラフィー(SEC)で確認した。液体クロマトグラフィー装置としてWaters社製の2695 型セパレーションモジュール又はe2695型セパレーションモジュールを用い、UV検出器としてWaters社製の2489型UV/Vis検出器を使用し、下記の条件で分析した。製造終了後7日間保存した場合の各成分の割合を表14に示す。製造終了後7日間保存した場合、実施例6の記載に従って製造した放射性複合体の凝集体の割合は、比較例4の記載に従って製造した放射性複合体の凝集体と同等であった。
カラム:TOSOH TSKgel guardcolumnSWXL(6mm×4cm),TOSOH TSKgel G3000SWXL(5μm、7.8×30cm)×2本(直列)
カラム温度:25℃付近の一定温度
移動相:0.2mol/Lアルギニン塩酸塩含有0.1mol/Lリン酸緩衝液(pH6.8)
流量:毎分 1.0mL
面積測定範囲:30分
検出波長:280nm
抗原結合活性は、評価する腫瘍切片に、ATCCから購入したEGFR高発現のヒト結腸がん由来細胞株であるSW48細胞、ATCCから購入したEGFR低発現のヒト結腸がん由来細胞株であるHCT-116及びECACCから購入したEGFR低発現のヒト大腸がん由来細胞株であるCOLO205細胞を追加した以外は、実施例1の記載に準じてin vitro ARGにより確認した(製造日点のみ)。また、それぞれの溶液に未標識のパニツムマブを添加した溶液(添加したパニツムマブ濃度:10nM)で同様に評価を行い、放射性複合体のEGFRに対する特異性を確認した。結果を図6に示す。実施例6の記載に従って製造した放射性複合体において、EGFRに対する結合活性が確認された。実施例6に従って製造した放射性複合体は、A431腫瘍切片、SNU-16腫瘍切片、SW48腫瘍切片、HCT-116腫瘍切片及びCOLO205腫瘍切片に結合が確認され、A431腫瘍切片及びSW48腫瘍切片により強く結合し、EGFR発現依存的な結合活性が確認された。パニツムマブを添加した溶液では、評価に使用した全ての切片において、結合が阻害されており、結合のEGFR特異性が確認された。
培養細胞を用いて、実施例6の記載に従って製造した放射性複合体の殺細胞効果を確認した。COLO205細胞(RPMI 1640培地)、HCT-116細胞(MaCoy’s 5A培地)、SW48細胞(Leibovitz’s L-15培地)、ECACCから購入したEGFR高発現であるヒト膵臓がん由来細胞株であるMIAPaCa-2細胞(D-MEM培地)、ATCCから購入したEGFR高発現である非小細胞肺がん由来細胞株であるNCI-H358細胞(RPMI 1640培地)をそれぞれ適した培地で培養し、実施例6に従って製造した放射性複合体を0、0.001、0.01、0.03、0.1、0.3、1、3、10、30kBq/mL(パニツムマブとして0.000764、0.00764、0.0229、0.0764、0.229、0.764、2.29、7.64、22.9μg/mL)となるよう各培地で希釈し,細胞に添加した。また、未標識のパニツムマブを各放射能濃度のサンプルと同様の抗体濃度になるように添加し、培養した。サンプル添加から120時間後、培地にCellTiter-Glo(登録商標)2.0 Cell Viability Assay(Promega社製)を添加し、マイクロプレートリーダー(SpectraMax i3x、モレキュラーデバイス社製)を用いて化学発光を検出し、生細胞数を算出した。算出された生細胞数に対し、抗体を添加していない条件の場合の生細胞数との比率を取り,殺細胞効果を評価した。結果を図7A~7Cに示す。また、得られた結果をGraphPad Prism7(GraphPad Software社製)を用いて、非線形直線回帰法によりフィッティングし,EC50を算出した。その結果、実施例6の記載に従って製造した放射性複合体の殺細胞効果におけるEC50は、SW48細胞に対しては0.5pM、NCI-H358細胞に対しては2.8pM、COLO205細胞に対しては7.3pMとなった。また、未標識のパニツムマブでは、添加した最大濃度(抗体濃度:156nM)以下では、殺細胞効果は確認されなかった。
評価細胞において、KRAS(v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog)、及びBRAF(v-raf murine sarcoma viral oncogene homolog B1)に変異を有する細胞を含め、未標識のパニツムマブでは殺細胞効果が確認されていない細胞においても、225Ac錯体標識パニツムマブでは、殺細胞効果が確認された。
実施例6の記載に従って製造した放射性複合体の培養細胞に対するアポトーシス誘導を確認した。
ヒト大腸がん由来細胞であるSW48細胞、COLO205細胞を実施例9と同様の条件で培養し、実施例6の記載に従って製造した放射性複合体を0、0.001、0.01、0.03、0.1、0.3、1、3kBq/mL(パニツムマブとして0.00764、0.0764、0.229、0.764、2.29、7.64、22.9μg/mL)となるよう添加した。また、未標識のパニツムマブを各放射能濃度の群と同様の抗体濃度になるように添加し、培養した。サンプル添加72時間後、アポトーシスアッセイキット(Caspase-Glo(登録商標)3/7 Assay、Promega社製)を添加し、Caspase-3/7の活性を、マイクロプレートリーダーを用いて検出した。その結果を図8に示す。両細胞とも、未標識のパニツムマブではアポトーシスの誘導は確認されなかったが、225Ac錯体標識パニツムマブでは、添加放射能依存的にCaspase-3/7の活性が増加しており、放射線によるアポトーシス誘導が確認された。
実施例6の記載に従って製造した放射性複合体の培養細胞に対するDNA二重鎖切断効果を確認した。
SW48細胞、MIAPaCa-2細胞、NCI-H358細胞を実施例9と同様に培養し、実施例6の記載に従って製造した放射性複合体を1kBq/mL、10kBq/mL、30kBq/mL(パニツムマブとして3.73、37.3、112μg/mL)となるように添加し、培養した。サンプル添加48時間後、DNAダメージ検出キット(DNA Damage Detection Kit-γH2AX-Green、同仁化学研究所製)により、γH2AXを染色し、DAPI含有水溶性マウント剤(ProLongTM Diamond Antifade Mountant with DAPI、Thermo Fisher Scientific社製)を用いて、核染色及び封入を行った。封入後、HSオールインワン蛍光顕微鏡(BZ-9000、キーエンス社製)を用いて、γH2AX陽性部位及び細胞核を検出した。その結果を図9A~9Cに示す。各細胞とも、添加放射能依存的にγH2AX陽性細胞の割合が増加しており、放射線によるDNA二重鎖切断が確認された。
マウスを用いて、COLO205細胞の皮下担癌モデルを作製し、実施例6の記載に従って製造した放射性複合体の抗腫瘍効果を確認した。
ECACCから購入したEGFR高発現であるヒト大腸がん由来細胞株であるCOLO205細胞をDMEM(gibco、サーモフィッシャーサイエンティフィック社製)に懸濁し、6週齢の雌性BALB/c nu/nu(日本チャールス・リバー社製)の脇腹皮下に5×106cells投与して担癌マウスを作製した。担癌処置後、腫瘍体積がおよそ100~300mm3であることを確認し、腫瘍径測定に適した形状の個体から無作為に群分けを実施した。その際の各マウスの腫瘍体積と体重は以下の表15に示す。
マウスを用いて、HCT-116細胞の皮下担癌モデルを作製し、実施例6の記載に従って製造した放射性複合体の抗腫瘍効果を確認した。
ATCCから購入したEGFR高発現であるヒト結腸がん由来細胞株であるHCT-116細胞をDMEM(gibco、サーモフィッシャーサイエンティフィック社製)に懸濁し、使用した点以外は実施例12と同様に抗腫瘍効果を確認した。各溶液を投与した際の各マウスの腫瘍体積と体重は以下の表16に示す。
マウスを用いて、SW48細胞の皮下担癌モデルを作製し、実施例6の記載に従って製造した放射性複合体の抗腫瘍効果を確認した。
ATCCから購入したEGFR高発現であるヒト結腸がん由来細胞株であるSW48細胞をDMEM(gibco、サーモフィッシャーサイエンティフィック社製)に懸濁し、使用した点以外は実施例12と同様に抗腫瘍効果を確認した。各溶液を投与した際の各マウスの腫瘍体積と体重は以下の表17に示す。
マウスを用いて、COLO205細胞の皮下担癌モデルを作製し、実施例6の記載に従って製造した放射性複合体の抗腫瘍効果を既存薬と比較した。
実施例12と同様に、COLO205細胞を担癌したマウスを作製し、抗腫瘍効果を確認した。各溶液を投与した際の各マウスの腫瘍体積と体重は以下の表18に示す。
実施例6の記載に従って製造した放射性複合体を各動物種(ヒト(ヒト血漿(プール、ヘパリン)、コスモバイオ社製)、マウス(マウス血漿プール BALB/c-nu系統、日本チャールス・リバー社製)、ラット(血漿(プール) Wistar、日本チャールス・リバー社製)、サル(カニクイザル血漿、日本チャールス・リバー社製))の血漿中に37℃で2週間保存し、各時間点(0日点、1日点、7日点、14日点(ヒト血漿のみ))での225Ac標識パニツムマブの血漿中での安定性を評価した。各動物種の血漿を37℃でインキュベートし、実施例6の記載に従って製造した放射性複合体を最終濃度で100kBq/mLとなるように添加した。各評価時間点において、Dynabeads(登録商標) Protein G(Thermo Fisher Scientific社製)を用いて、免疫沈降を行い、0.1%Tween20含有PBSによる洗浄後、Protein Gと結合した抗体を回収した。ビーズの洗浄に用いた0.1%Tween20含有PBSは回収し、回収した洗浄液の放射能、及び回収した抗体の放射能をオートウェルガンマカウンター(2480 WIZARD2 ガンマカウンター、PerkinElmer社製)を用いて測定し、ビーズの洗浄に用いた0.1%Tween20含有PBSの放射能と回収した抗体の放射能の合計に対する、回収した抗体の放射能の比率を算出することでProtein Gと結合した225Ac標識パニツムマブの割合を評価した。その結果を表19に示す。表内の数値は、ビーズの洗浄に用いた0.1%Tween20含有PBSの放射能と回収した抗体の放射能の合計に対する、回収した抗体の放射能の比率の平均値±標準偏差(n=3)を表している。
実施例12に準じてマウスを用いてCOLO205細胞の皮下担癌モデルを作製し、実施例7の記載に従って製造した放射性複合体の腫瘍集積性を確認した。
ATCCから購入したEGFR高発現のヒト大腸がん由来細胞株であるCOLO205細胞をDMEM培地に懸濁し、5週齢の雌性BALB/c nu/nu(日本チャールス・リバー社製)の脇腹皮下に5×106cells投与して担癌マウスを作製した。腫瘍体積がおおよそ100~250mm3となるまで成長させ、実施例7の記載に従って製造した放射性複合体を約6MBq/匹(各n=3)の用量で尾静脈内投与した。投与72時間後及び120時間後に小動物PETイメージング装置を用いて評価2と同様の条件で撮像を行った。
PET撮像を実施した結果の代表例を図15に示す。画像内の矢印は担癌したCOLO205細胞に由来する腫瘍を示す。撮像した各マウスにおいて腫瘍及び筋肉(大腿筋)にVOIを設定し、SUV(Standard Uptake Value)を算出した場合、投与72時間後では、腫瘍においては3.18±0.72、筋肉においては0.48±0.02となり、投与120時間後では腫瘍においては4.38±0.96、筋肉においては0.48±0.05となった。その値を用いて、筋肉に対する腫瘍の放射能集積比率を算出した結果、投与72時間後では6.67±1.52であり、投与120時間後では9.19±2.02となり、腫瘍には他の臓器と比較して放射能が高い濃度で集積し、EGFR陽性腫瘍の描出が可能であった。
Claims (14)
- ペプチドで部位特異的に修飾された抗EGFR抗体とキレート剤との複合体であって、
前記キレート剤に放射性金属核種がキレート化しており、
前記ペプチドとキレート剤とがリンカー(L)を介して連結しており、前記リンカー(L)はチオウレア結合を含まない、複合体。 - 前記キレート剤がDOTAGA(α-(2-Carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)である、請求項1に記載の複合体。
- 前記ペプチドが、下記の式:
(Xa)-Xaa1-(Xb)-Xaa2-(Xc)-Xaa3-(Xd)・・・(i)
(式(i)中、Xa、Xb、Xc及びXdは、それぞれ、連続するa個のX、連続するb個のX、連続するc個のX、及び連続するd個のXを表し、
Xは、側鎖にチオール基及びハロアセチル基のいずれも有しないアミノ酸残基であり、
a、b、c及びdはそれぞれ独立に1以上5以下の整数で、かつa+b+c+d≦14を満たし
Xaa1及びXaa3は、それぞれ独立に、
側鎖にチオール基を有するアミノ酸に由来するアミノ酸残基、又は、側鎖にハロアセチル基を有するアミノ酸に由来するアミノ酸残基を表し、ただし、Xaa1及びXaa3のいずれか一方がチオール基を有するアミノ酸に由来するアミノ酸残基であり、
Xaa1及びXaa3が連結することで、環構造が形成されており、
Xaa2は、リシン残基、アルギニン残基、システイン残基、アスパラギン酸残基、グルタミン酸残基、2-アミノスベリン酸、又はジアミノプロピオン酸であり、かつXaa2が架橋剤で修飾されている。)
で表される、13~17アミノ酸残基からなるアミノ酸配列である、請求項1又は2に記載の複合体。 - 前記放射性金属核種がAc-225、Y-90、Lu-177又はZr-89である、請求項1乃至3いずれか一項に記載の複合体。
- 前記ペプチドとの連結部位と前記ペプチドとの間に、ポリエチレングリコール基を含む、請求項5に記載の複合体。
- 前記抗EGFR抗体がセツキシマブまたはパニツムマブである、請求項1乃至7いずれか一項に記載の複合体。
- 請求項1乃至8いずれか一項に記載の複合体を有効成分として含有する放射性医薬。
- がんの放射線内用療法に用いられる、請求項9に記載の放射性医薬。
- がんの診断に用いられる、請求項9に記載の放射性医薬。
- 請求項10に記載された放射性医薬を用いたがんの放射線内用療法に併用される、請求項11に記載の放射性医薬。
- 放射性金属核種がキレート化したキレート剤と、抗EGFR抗体との複合体を有効成分として含有し
抗EGFR抗体とキレート剤との連結にチオウレア結合を含まない、下記(1)または(2)の条件を満たす放射性医薬:
(1)前記放射性金属核種が177Lu又は90Yであって、室温で7日間保管した時の前記複合体の放射化学的純度が90%以上である。
(2)前記放射性金属核種が225Acであって、室温で14日間保管した時の前記複合体の放射化学的純度が90%以上である。 - 放射性金属核種がキレート化したキレート剤と、抗EGFR抗体との複合体を有効成分として含有し
抗EGFR抗体とキレート剤との連結にチオウレア結合を含まず、
前記放射性金属核種の半減期を基準として、前記半減期の1以上5以下の倍数の期間経過時点において、前記複合体の放射化学的純度が90%以上である放射性医薬。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22781261.7A EP4317188A1 (en) | 2021-03-31 | 2022-03-31 | Radioactive complex of anti-egfr antibody, and radiopharmaceutical |
CA3215787A CA3215787A1 (en) | 2021-03-31 | 2022-03-31 | Radioactive complex of anti-egfr antibody, and radiopharmaceutical |
CN202280027467.8A CN117377690A (zh) | 2021-03-31 | 2022-03-31 | 抗egfr抗体的放射性复合物和放射性药物 |
KR1020237036890A KR20230163487A (ko) | 2021-03-31 | 2022-03-31 | 항egfr 항체의 방사성 복합체 및 방사성 의약 |
US18/553,443 US20240207463A1 (en) | 2021-03-31 | 2022-03-31 | Radioactive complex of anti-egfr antibody, and radiopharmaceutical |
AU2022250323A AU2022250323A1 (en) | 2021-03-31 | 2022-03-31 | Radioactive complex of anti-egfr antibody, and radiopharmaceutical |
JP2023511723A JPWO2022211051A1 (ja) | 2021-03-31 | 2022-03-31 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021062104 | 2021-03-31 | ||
JP2021-062104 | 2021-03-31 | ||
JP2021-179348 | 2021-11-02 | ||
JP2021179348 | 2021-11-02 | ||
JP2022-021670 | 2022-02-15 | ||
JP2022021670 | 2022-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022211051A1 true WO2022211051A1 (ja) | 2022-10-06 |
Family
ID=83456595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/016647 WO2022211051A1 (ja) | 2021-03-31 | 2022-03-31 | 抗egfr抗体の放射性複合体、及び、放射性医薬 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240207463A1 (ja) |
EP (1) | EP4317188A1 (ja) |
JP (1) | JPWO2022211051A1 (ja) |
KR (1) | KR20230163487A (ja) |
AU (1) | AU2022250323A1 (ja) |
CA (1) | CA3215787A1 (ja) |
TW (1) | TW202304522A (ja) |
WO (1) | WO2022211051A1 (ja) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004509152A (ja) * | 2000-05-12 | 2004-03-25 | ユニバーシティ ホスピタル | 放射性金属標識分子のプロキレート剤 |
JP2005047934A (ja) | 1988-09-15 | 2005-02-24 | Rorer Internatl Overseas Inc | 抗腫瘍剤と共にモノクローナル抗体を用いた治療剤 |
JP2013512918A (ja) * | 2009-12-04 | 2013-04-18 | イミューノメディクス、インコーポレイテッド | タンパク質、ペプチドおよび他の分子の改善されたf−18標識化のための方法および組成物 |
WO2016186206A1 (ja) | 2015-05-20 | 2016-11-24 | 国立大学法人鹿児島大学 | IgG結合ペプチドによる抗体の特異的修飾 |
WO2017217347A1 (ja) | 2016-06-13 | 2017-12-21 | 国立大学法人鹿児島大学 | IgG結合ペプチドによる部位特異的RI標識抗体 |
WO2018230257A1 (ja) | 2017-06-16 | 2018-12-20 | 国立大学法人鹿児島大学 | IgG結合ペプチド、及び該ペプチドによる抗体の特異的修飾 |
WO2019203191A1 (ja) * | 2018-04-16 | 2019-10-24 | 日本メジフィジックス株式会社 | 修飾抗体、および、放射性金属標識抗体 |
US20200353105A1 (en) * | 2019-05-10 | 2020-11-12 | Janssen Biotech, Inc. | Macrocyclic Chelators and Methods of Use Thereof |
JP2021506842A (ja) * | 2017-12-18 | 2021-02-22 | ヤンセン バイオテツク,インコーポレーテツド | ポリペプチドの放射性標識 |
JP2021062104A (ja) | 2019-10-16 | 2021-04-22 | トヨタ自動車株式会社 | 歩行訓練システム、装具、及び作動方法 |
WO2021080008A1 (ja) | 2019-10-24 | 2021-04-29 | 国立大学法人 鹿児島大学 | 1価ccap生成物の製造方法 |
JP2021179348A (ja) | 2020-05-13 | 2021-11-18 | Koa株式会社 | ガスセンサ用差分生成回路 |
JP2022021670A (ja) | 2020-07-22 | 2022-02-03 | 株式会社サンセイアールアンドディ | 遊技機 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017214308A (ja) | 2016-05-31 | 2017-12-07 | 国立研究開発法人量子科学技術研究開発機構 | 放射性医薬組成物、及び、放射能標識抗体のスクリーニング方法 |
-
2022
- 2022-03-31 TW TW111112631A patent/TW202304522A/zh unknown
- 2022-03-31 WO PCT/JP2022/016647 patent/WO2022211051A1/ja active Application Filing
- 2022-03-31 EP EP22781261.7A patent/EP4317188A1/en active Pending
- 2022-03-31 JP JP2023511723A patent/JPWO2022211051A1/ja active Pending
- 2022-03-31 KR KR1020237036890A patent/KR20230163487A/ko unknown
- 2022-03-31 US US18/553,443 patent/US20240207463A1/en active Pending
- 2022-03-31 CA CA3215787A patent/CA3215787A1/en active Pending
- 2022-03-31 AU AU2022250323A patent/AU2022250323A1/en active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005047934A (ja) | 1988-09-15 | 2005-02-24 | Rorer Internatl Overseas Inc | 抗腫瘍剤と共にモノクローナル抗体を用いた治療剤 |
JP2004509152A (ja) * | 2000-05-12 | 2004-03-25 | ユニバーシティ ホスピタル | 放射性金属標識分子のプロキレート剤 |
JP2013512918A (ja) * | 2009-12-04 | 2013-04-18 | イミューノメディクス、インコーポレイテッド | タンパク質、ペプチドおよび他の分子の改善されたf−18標識化のための方法および組成物 |
WO2016186206A1 (ja) | 2015-05-20 | 2016-11-24 | 国立大学法人鹿児島大学 | IgG結合ペプチドによる抗体の特異的修飾 |
WO2017217347A1 (ja) | 2016-06-13 | 2017-12-21 | 国立大学法人鹿児島大学 | IgG結合ペプチドによる部位特異的RI標識抗体 |
WO2018230257A1 (ja) | 2017-06-16 | 2018-12-20 | 国立大学法人鹿児島大学 | IgG結合ペプチド、及び該ペプチドによる抗体の特異的修飾 |
JP2021506842A (ja) * | 2017-12-18 | 2021-02-22 | ヤンセン バイオテツク,インコーポレーテツド | ポリペプチドの放射性標識 |
WO2019203191A1 (ja) * | 2018-04-16 | 2019-10-24 | 日本メジフィジックス株式会社 | 修飾抗体、および、放射性金属標識抗体 |
US20200353105A1 (en) * | 2019-05-10 | 2020-11-12 | Janssen Biotech, Inc. | Macrocyclic Chelators and Methods of Use Thereof |
JP2021062104A (ja) | 2019-10-16 | 2021-04-22 | トヨタ自動車株式会社 | 歩行訓練システム、装具、及び作動方法 |
WO2021080008A1 (ja) | 2019-10-24 | 2021-04-29 | 国立大学法人 鹿児島大学 | 1価ccap生成物の製造方法 |
JP2021179348A (ja) | 2020-05-13 | 2021-11-18 | Koa株式会社 | ガスセンサ用差分生成回路 |
JP2022021670A (ja) | 2020-07-22 | 2022-02-03 | 株式会社サンセイアールアンドディ | 遊技機 |
Non-Patent Citations (2)
Title |
---|
BERNHARD ET AL.: "DOTAGA-Anhydride: A Valuable Building Block for the Preparation of DOTA-Like Chelating Agents", CHEM. EUR. J., vol. 18, 2012, pages 7834 - 7841, XP055465245, DOI: 10.1002/chem.201200132 |
SANDRA HESKAMP, RENé RAAVé, OTTO BOERMAN, MARK RIJPKEMA, VICTOR GONCALVES, FRANCK DENAT: "89 Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89 Zr Radiochemistry", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 28, no. 9, 20 September 2017 (2017-09-20), US , pages 2211 - 2223, XP055734862, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.7b00325 * |
Also Published As
Publication number | Publication date |
---|---|
EP4317188A1 (en) | 2024-02-07 |
JPWO2022211051A1 (ja) | 2022-10-06 |
AU2022250323A1 (en) | 2023-11-09 |
TW202304522A (zh) | 2023-02-01 |
US20240207463A1 (en) | 2024-06-27 |
CA3215787A1 (en) | 2022-10-06 |
KR20230163487A (ko) | 2023-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7036996B2 (ja) | Ri標識されたヒト化抗体 | |
TW202128732A (zh) | 放射性金屬標定抗體、其製造方法、螯合連接子、及肽修飾抗體 | |
WO2022211051A1 (ja) | 抗egfr抗体の放射性複合体、及び、放射性医薬 | |
WO2022224980A1 (ja) | 抗cd20抗体の放射性複合体、及び、放射性医薬 | |
WO2022080481A1 (ja) | 抗her2抗体の放射性複合体、及び、放射性医薬 | |
WO2023157822A1 (ja) | 抗vegf抗体の放射性複合体、及び、放射性医薬 | |
WO2023033022A1 (ja) | 脱グリコシル化抗体の放射性複合体、及び、放射性医薬 | |
WO2022225007A1 (ja) | 放射性抗腫瘍剤 | |
WO2023277144A1 (ja) | Heg1タンパク質に結合するヒト化抗体および当該抗体と放射性核種との複合体 | |
WO2022225006A1 (ja) | β線を放出する核種で標識されたヒト化抗体 | |
US20240316228A1 (en) | Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product | |
WO2024090488A1 (ja) | 放射性医薬組成物 | |
CN117377690A (zh) | 抗egfr抗体的放射性复合物和放射性药物 | |
CN117769440A (zh) | 抗cd20抗体的放射性复合物和放射性药物 | |
CN118695878A (zh) | 抗vegf抗体的放射性复合物和放射性药物 | |
CN116456992A (zh) | 抗her2抗体的放射性复合物和放射性药物 | |
JP2024506070A (ja) | 新規her2結合ポリペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22781261 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023511723 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 3215787 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18553443 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280027467.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022250323 Country of ref document: AU Ref document number: 2022250323 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20237036890 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202347073679 Country of ref document: IN Ref document number: 202392736 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11202307408U Country of ref document: SG Ref document number: 2022781261 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022781261 Country of ref document: EP Effective date: 20231031 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022250323 Country of ref document: AU Date of ref document: 20220331 Kind code of ref document: A |